EP2557923A1 - Traitement de cancers présentant des mutations k-ras - Google Patents
Traitement de cancers présentant des mutations k-rasInfo
- Publication number
- EP2557923A1 EP2557923A1 EP11769663A EP11769663A EP2557923A1 EP 2557923 A1 EP2557923 A1 EP 2557923A1 EP 11769663 A EP11769663 A EP 11769663A EP 11769663 A EP11769663 A EP 11769663A EP 2557923 A1 EP2557923 A1 EP 2557923A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- mmol
- substituted
- methyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 68
- 230000035772 mutation Effects 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title description 14
- 238000000034 method Methods 0.000 claims abstract description 220
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims abstract description 38
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims abstract description 38
- 101710113436 GTPase KRas Proteins 0.000 claims abstract description 37
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract description 25
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims abstract description 18
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims abstract description 16
- 229940116355 PI3 kinase inhibitor Drugs 0.000 claims abstract description 9
- 108010014186 ras Proteins Proteins 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 655
- -1 XL- 147 Chemical compound 0.000 claims description 161
- 125000001072 heteroaryl group Chemical group 0.000 claims description 74
- 125000000623 heterocyclic group Chemical group 0.000 claims description 71
- 125000001931 aliphatic group Chemical group 0.000 claims description 61
- 125000003118 aryl group Chemical group 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052717 sulfur Inorganic materials 0.000 claims description 35
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000000651 prodrug Substances 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- 125000002252 acyl group Chemical group 0.000 claims description 26
- 125000003282 alkyl amino group Chemical group 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 26
- 125000003342 alkenyl group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 102000003964 Histone deacetylase Human genes 0.000 claims description 23
- 108090000353 Histone deacetylase Proteins 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
- 125000003107 substituted aryl group Chemical group 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 17
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 12
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 11
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 9
- 125000004442 acylamino group Chemical group 0.000 claims description 9
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 8
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 6
- 229960000237 vorinostat Drugs 0.000 claims description 6
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 5
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 5
- 229910020008 S(O) Inorganic materials 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 230000019491 signal transduction Effects 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- OYYVWNDMOQPMGE-SDQBBNPISA-N (5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound OC1=CC(F)=CC=C1C(O1)=CC=C1\C=C/1C(=O)NC(=O)S\1 OYYVWNDMOQPMGE-SDQBBNPISA-N 0.000 claims description 4
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 4
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 4
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 4
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 4
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 claims description 3
- 125000005122 aminoalkylamino group Chemical group 0.000 claims description 3
- 229950006418 dactolisib Drugs 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 3
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- VLULRUCCHYVXOH-UHFFFAOYSA-N 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound CC1=CC=CC=C1CN1C(=O)C(CN(CC=2C=CC=CC=2)CC2)=C2N2CCN=C21 VLULRUCCHYVXOH-UHFFFAOYSA-N 0.000 claims description 2
- XLJORQYAOTYVQS-OGCOKEDGSA-N 17-hydroxywortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CC[C@H](O)[C@@]2(C)C[C@H]1OC(C)=O XLJORQYAOTYVQS-OGCOKEDGSA-N 0.000 claims description 2
- 230000007730 Akt signaling Effects 0.000 claims description 2
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 claims description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 claims description 2
- TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 claims description 2
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 125000005096 aminoalkylaminocarbonyl group Chemical group 0.000 claims description 2
- 229950003628 buparlisib Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 claims description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960003445 idelalisib Drugs 0.000 claims description 2
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 2
- QTHCAAFKVUWAFI-DJKKODMXSA-N n-[(e)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide Chemical compound C=1N=C2C=CC(Br)=CN2C=1/C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C QTHCAAFKVUWAFI-DJKKODMXSA-N 0.000 claims description 2
- JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 claims description 2
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 2
- 229960005184 panobinostat Drugs 0.000 claims description 2
- 229910052705 radium Inorganic materials 0.000 claims description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
- 229960003452 romidepsin Drugs 0.000 claims description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 2
- 108010091666 romidepsin Proteins 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 15
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 102000016914 ras Proteins Human genes 0.000 abstract description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 214
- 239000007787 solid Substances 0.000 description 210
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 209
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 206
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 182
- 239000000203 mixture Substances 0.000 description 152
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 148
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 135
- 239000000243 solution Substances 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 126
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 114
- 229910001868 water Inorganic materials 0.000 description 112
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 86
- 238000002360 preparation method Methods 0.000 description 67
- 235000019441 ethanol Nutrition 0.000 description 61
- 229940126214 compound 3 Drugs 0.000 description 56
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 55
- LZMKLGSLUKISQE-UHFFFAOYSA-N hydroxylamine;methanol Chemical compound OC.ON LZMKLGSLUKISQE-UHFFFAOYSA-N 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- 235000019439 ethyl acetate Nutrition 0.000 description 50
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 48
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 46
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 125000004432 carbon atom Chemical group C* 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 34
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 32
- 239000012267 brine Substances 0.000 description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- 239000002904 solvent Substances 0.000 description 29
- 150000003254 radicals Chemical class 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 27
- 239000003921 oil Substances 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- 235000011056 potassium acetate Nutrition 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 23
- 235000017557 sodium bicarbonate Nutrition 0.000 description 23
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 22
- 238000004440 column chromatography Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 125000004429 atom Chemical group 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- LXJLGYYEYXALIX-UHFFFAOYSA-N ethyl 2-[[2-(3-acetamidophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(NC(C)=O)C=CC=3)=NC(N3CCOCC3)=C2S1 LXJLGYYEYXALIX-UHFFFAOYSA-N 0.000 description 19
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 230000001588 bifunctional effect Effects 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 229910002666 PdCl2 Inorganic materials 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 12
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 125000002877 alkyl aryl group Chemical group 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 10
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 9
- 125000005024 alkenyl aryl group Chemical group 0.000 description 9
- 125000005025 alkynylaryl group Chemical group 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- BFDRQDZWKVCARB-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2,2-dimethylpropyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)(C)C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BFDRQDZWKVCARB-UHFFFAOYSA-N 0.000 description 9
- SIRUPXFAJWRELQ-UHFFFAOYSA-N ethyl 2-[2,2-dimethylpropyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)(C)C)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SIRUPXFAJWRELQ-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- YDQUTKQHRCXBMC-UHFFFAOYSA-N n-hydroxy-5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]pentanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C4=CN(CCCCC(=O)NO)N=C4C=CC=3)=NC(N3CCOCC3)=C2S1 YDQUTKQHRCXBMC-UHFFFAOYSA-N 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- PFAKZIZFIXKDFP-UHFFFAOYSA-N 2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C=12SC(C=O)=CC2=NC(Cl)=NC=1N1CCOCC1 PFAKZIZFIXKDFP-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- CJYQQUPRURWLOW-YDLUHMIOSA-M dmsc Chemical compound [Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O CJYQQUPRURWLOW-YDLUHMIOSA-M 0.000 description 8
- SAUWUKGEDYGTQA-UHFFFAOYSA-N ethyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoate Chemical compound C=12SC(CN(CCCC(=O)OCC)C(=O)OC(C)(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 SAUWUKGEDYGTQA-UHFFFAOYSA-N 0.000 description 8
- QAKSSPKPCAQCAU-UHFFFAOYSA-N ethyl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]hexanoate Chemical compound C=12SC(CNCCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 QAKSSPKPCAQCAU-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- KJIODOACRIRBPB-UHFFFAOYSA-N 4-bromo-1h-indazole Chemical compound BrC1=CC=CC2=C1C=NN2 KJIODOACRIRBPB-UHFFFAOYSA-N 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- FQOUFMHJMYJZOF-UHFFFAOYSA-N ethyl 4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]butanoate Chemical compound C=12SC(CN(C)CCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FQOUFMHJMYJZOF-UHFFFAOYSA-N 0.000 description 7
- ZIFUEKHQTOKJSJ-UHFFFAOYSA-N ethyl 5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]pentanoate Chemical compound C1=CC=C2N(CCCCC(=O)OCC)N=CC2=C1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 ZIFUEKHQTOKJSJ-UHFFFAOYSA-N 0.000 description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- HOQPCMHERISQFY-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]propan-1-amine Chemical compound C=12SC(CNCCC)=CC2=NC(Cl)=NC=1N1CCOCC1 HOQPCMHERISQFY-UHFFFAOYSA-N 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 108700042226 ras Genes Proteins 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- TZYNTKYTACHQAE-UHFFFAOYSA-N n-hydroxy-3-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]propanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NN(CCC(=O)NO)C=4C=CC=3)=NC(N3CCOCC3)=C2S1 TZYNTKYTACHQAE-UHFFFAOYSA-N 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- SPLBPPMPKQJGSP-UHFFFAOYSA-N (2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methanamine Chemical compound C=12SC(CN)=CC2=NC(Cl)=NC=1N1CCOCC1 SPLBPPMPKQJGSP-UHFFFAOYSA-N 0.000 description 5
- AQECFYPZMBRCIA-UHFFFAOYSA-N 2,4-dichlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2SC=CC2=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 5
- BZULTSHGWOGXKK-UHFFFAOYSA-N 4-[2-chloro-6-[(4-methylsulfanyloxypiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(OSC)CCN1CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BZULTSHGWOGXKK-UHFFFAOYSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
- 239000012346 acetyl chloride Substances 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 125000004171 alkoxy aryl group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- VUWBNIOBCLBZPH-UHFFFAOYSA-N ethyl 5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]pentanoate Chemical compound C=1C=CC2=NN(CCCCC(=O)OCC)C=C2C=1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 VUWBNIOBCLBZPH-UHFFFAOYSA-N 0.000 description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- KMAWENLAUQIUBD-UHFFFAOYSA-N methyl 5-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentanoate Chemical compound C=12SC(CN(CCCCC(=O)OC)C(=O)OC(C)(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 KMAWENLAUQIUBD-UHFFFAOYSA-N 0.000 description 5
- PYTWIIUKFHEGGC-UHFFFAOYSA-N methyl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 PYTWIIUKFHEGGC-UHFFFAOYSA-N 0.000 description 5
- VEEQZIRXFALOMR-UHFFFAOYSA-N n-hydroxy-2-[methyl-[[2-(2-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC(C)=NC=1)=NC=2N1CCOCC1 VEEQZIRXFALOMR-UHFFFAOYSA-N 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- BOSBNEDQPWTVAQ-UHFFFAOYSA-N propan-2-yl 6-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC(C)C)=CC=C1NCC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BOSBNEDQPWTVAQ-UHFFFAOYSA-N 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- UJOJBFAUAVIWPP-UHFFFAOYSA-N (2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methanol Chemical compound C=12SC(CO)=CC2=NC(Cl)=NC=1N1CCOCC1 UJOJBFAUAVIWPP-UHFFFAOYSA-N 0.000 description 4
- REHYBWIGNLPYTA-JXMROGBWSA-N (e)-n-hydroxy-3-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]phenyl]prop-2-enamide Chemical compound C=1C=C(\C=C\C(=O)NO)C=CC=1N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 REHYBWIGNLPYTA-JXMROGBWSA-N 0.000 description 4
- SJUUPNNMQDIXIP-RMKNXTFCSA-N (e)-n-hydroxy-3-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SJUUPNNMQDIXIP-RMKNXTFCSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- FGYOBHBOPXDZMF-UHFFFAOYSA-N 1-(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)-n-methylmethanamine Chemical compound C=12SC(CNC)=CC2=NC(Cl)=NC=1N1CCOCC1 FGYOBHBOPXDZMF-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- ROXIFDKIQYPVCY-UHFFFAOYSA-N 2-[[2-(2-amino-4-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C(=NC(N)=NC=1)C)=NC=2N1CCOCC1 ROXIFDKIQYPVCY-UHFFFAOYSA-N 0.000 description 4
- HAHQWFVYINSSIG-UHFFFAOYSA-N 2-[[2-(3-acetamidophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(NC(C)=O)C=CC=1)=NC=2N1CCOCC1 HAHQWFVYINSSIG-UHFFFAOYSA-N 0.000 description 4
- DSONSPJGTUIWAF-UHFFFAOYSA-N 2-[[2-(3-aminophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(N)C=CC=1)=NC=2N1CCOCC1 DSONSPJGTUIWAF-UHFFFAOYSA-N 0.000 description 4
- QPEOIGMQHQXVHA-UHFFFAOYSA-N 2-[[2-(4-acetamidophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(NC(C)=O)=CC=1)=NC=2N1CCOCC1 QPEOIGMQHQXVHA-UHFFFAOYSA-N 0.000 description 4
- ZQFAPAMHVSXWMY-UHFFFAOYSA-N 2-[[2-(6-aminopyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC(N)=CC=1)=NC=2N1CCOCC1 ZQFAPAMHVSXWMY-UHFFFAOYSA-N 0.000 description 4
- BLKMBNOEZWSRGU-UHFFFAOYSA-N 2-[[2-[2-(dimethylamino)pyrimidin-5-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound C1=NC(N(C)C)=NC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 BLKMBNOEZWSRGU-UHFFFAOYSA-N 0.000 description 4
- DFNQUKGIDCSUPW-UHFFFAOYSA-N 2-[[2-[3-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(CN)C=CC=1)=NC=2N1CCOCC1 DFNQUKGIDCSUPW-UHFFFAOYSA-N 0.000 description 4
- DTPBBEDURXHSOM-UHFFFAOYSA-N 2-[[2-[3-(dimethylamino)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound CN(C)C1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 DTPBBEDURXHSOM-UHFFFAOYSA-N 0.000 description 4
- IUVUCGHQOBTKLT-UHFFFAOYSA-N 2-[[2-[4-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(CN)=CC=1)=NC=2N1CCOCC1 IUVUCGHQOBTKLT-UHFFFAOYSA-N 0.000 description 4
- GZGOLDVPLRYKGK-UHFFFAOYSA-N 2-[butyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 GZGOLDVPLRYKGK-UHFFFAOYSA-N 0.000 description 4
- HKQMXHKNXRNUCF-UHFFFAOYSA-N 4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine Chemical compound C=12SC=CC2=NC(Cl)=NC=1N1CCOCC1 HKQMXHKNXRNUCF-UHFFFAOYSA-N 0.000 description 4
- NYMYGNLCILQUMT-UHFFFAOYSA-N 5-bromo-n,n-dimethylpyrimidin-2-amine Chemical compound CN(C)C1=NC=C(Br)C=N1 NYMYGNLCILQUMT-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- 229910020889 NaBH3 Inorganic materials 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 229940126540 compound 41 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- NCEXFFIQEINAEO-VURMDHGXSA-N ethyl (z)-2-(ethoxymethyl)-3-methoxyprop-2-enoate Chemical compound CCOC\C(=C\OC)C(=O)OCC NCEXFFIQEINAEO-VURMDHGXSA-N 0.000 description 4
- FWFVECCWPYHHAY-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-propylamino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCC)CC(SC1=2)=CC1=NC(Cl)=NC=2N1CCOCC1 FWFVECCWPYHHAY-UHFFFAOYSA-N 0.000 description 4
- WGCSHLUYKRADNA-UHFFFAOYSA-N ethyl 2-piperazin-1-ylpyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCNCC1 WGCSHLUYKRADNA-UHFFFAOYSA-N 0.000 description 4
- ZYEHTUIHXNUXEW-UHFFFAOYSA-N ethyl 6-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]hexanoate Chemical compound C=12SC(CNCCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 ZYEHTUIHXNUXEW-UHFFFAOYSA-N 0.000 description 4
- GGJPCRDVYPJJFB-UHFFFAOYSA-N ethyl 6-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]hexanoate Chemical compound C=1C=CC2=NN(CCCCCC(=O)OCC)C=C2C=1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 GGJPCRDVYPJJFB-UHFFFAOYSA-N 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- XXHOHJTVFUJJMT-UHFFFAOYSA-N n-(3-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(Br)=C1 XXHOHJTVFUJJMT-UHFFFAOYSA-N 0.000 description 4
- CGTZXRLVHFZVIE-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-2,2-dimethylpropan-1-amine Chemical compound C=12SC(CNCC(C)(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 CGTZXRLVHFZVIE-UHFFFAOYSA-N 0.000 description 4
- HFBWKMAPDOQZNZ-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methoxyethyl)amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCOC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 HFBWKMAPDOQZNZ-UHFFFAOYSA-N 0.000 description 4
- ZKAWXBWMUHZUOX-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methylpropyl)amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CC(C)C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 ZKAWXBWMUHZUOX-UHFFFAOYSA-N 0.000 description 4
- WAZYFRLJFZVEQM-UHFFFAOYSA-N n-hydroxy-2-[[2-(3-hydroxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(O)C=CC=1)=NC=2N1CCOCC1 WAZYFRLJFZVEQM-UHFFFAOYSA-N 0.000 description 4
- GZAPMNSRALRNRF-UHFFFAOYSA-N n-hydroxy-2-[[2-(3-methoxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound COC1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 GZAPMNSRALRNRF-UHFFFAOYSA-N 0.000 description 4
- DKNQJZZPXCRQBX-UHFFFAOYSA-N n-hydroxy-2-[[2-[2-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C(=CC=CC=1)CO)=NC=2N1CCOCC1 DKNQJZZPXCRQBX-UHFFFAOYSA-N 0.000 description 4
- CAKVTYSJPFVWCT-UHFFFAOYSA-N n-hydroxy-2-[[2-[3-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(CO)C=CC=1)=NC=2N1CCOCC1 CAKVTYSJPFVWCT-UHFFFAOYSA-N 0.000 description 4
- PMKSWLPJTZBVNA-UHFFFAOYSA-N n-hydroxy-2-[[2-[4-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(CO)=CC=1)=NC=2N1CCOCC1 PMKSWLPJTZBVNA-UHFFFAOYSA-N 0.000 description 4
- RXWSTGJYPIFWPA-UHFFFAOYSA-N n-hydroxy-2-[methyl-[(4-morpholin-4-yl-2-pyridin-3-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC=CC=1)=NC=2N1CCOCC1 RXWSTGJYPIFWPA-UHFFFAOYSA-N 0.000 description 4
- JSEVWCAPIWLOFE-UHFFFAOYSA-N n-hydroxy-2-[methyl-[[2-[3-(methylcarbamoyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 JSEVWCAPIWLOFE-UHFFFAOYSA-N 0.000 description 4
- XEDJNRNYKQMESF-UHFFFAOYSA-N n-hydroxy-4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 XEDJNRNYKQMESF-UHFFFAOYSA-N 0.000 description 4
- JPWAXTJUCSTPNX-UHFFFAOYSA-N n-hydroxy-5-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pentanamide Chemical compound C=12SC(CN(CCCCC(=O)NO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 JPWAXTJUCSTPNX-UHFFFAOYSA-N 0.000 description 4
- RBEKXPMXZFXYON-UHFFFAOYSA-N n-hydroxy-6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]hexanamide Chemical compound C=12SC(CN(CCCCCC(=O)NO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 RBEKXPMXZFXYON-UHFFFAOYSA-N 0.000 description 4
- USUKHNWASJITKV-UHFFFAOYSA-N n-hydroxy-6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]hexanamide Chemical compound C=12SC(CNCCCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 USUKHNWASJITKV-UHFFFAOYSA-N 0.000 description 4
- OHSHEUPWMYCFNS-UHFFFAOYSA-N n-hydroxy-7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]heptanamide Chemical compound C=12SC(CN(CCCCCCC(=O)NO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 OHSHEUPWMYCFNS-UHFFFAOYSA-N 0.000 description 4
- 230000009826 neoplastic cell growth Effects 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 4
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- LQEQVVBJQZOHHD-UHFFFAOYSA-N (2-bromophenyl)methyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1Br LQEQVVBJQZOHHD-UHFFFAOYSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 3
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 3
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 3
- QLXXLGBOXDYBGI-UHFFFAOYSA-N 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]ethanol Chemical compound C=12SC(CNCCO)=CC2=NC(Cl)=NC=1N1CCOCC1 QLXXLGBOXDYBGI-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- GETNSPCFXQQQDW-UHFFFAOYSA-N 2-[[2-(2-ethylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound C1=NC(CC)=NC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 GETNSPCFXQQQDW-UHFFFAOYSA-N 0.000 description 3
- KUSWHWLPLQWWAT-UHFFFAOYSA-N 2-[[2-(3-carbamoylphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(C=CC=1)C(N)=O)=NC=2N1CCOCC1 KUSWHWLPLQWWAT-UHFFFAOYSA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
- DSYSVUWIAUMZDQ-UHFFFAOYSA-N 3-bromo-5-fluoro-2-methylaniline Chemical compound CC1=C(N)C=C(F)C=C1Br DSYSVUWIAUMZDQ-UHFFFAOYSA-N 0.000 description 3
- YBNPCJSZMYHDDR-UHFFFAOYSA-N 3-bromo-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(Br)=C1 YBNPCJSZMYHDDR-UHFFFAOYSA-N 0.000 description 3
- ODJFDWIECLJWSR-UHFFFAOYSA-N 3-bromobenzamide Chemical compound NC(=O)C1=CC=CC(Br)=C1 ODJFDWIECLJWSR-UHFFFAOYSA-N 0.000 description 3
- VUKKRGQLFZMXNZ-UHFFFAOYSA-N 4-bromo-6-fluoro-1h-indazole Chemical compound FC1=CC(Br)=C2C=NNC2=C1 VUKKRGQLFZMXNZ-UHFFFAOYSA-N 0.000 description 3
- SQOJDBHJUUGQJP-UHFFFAOYSA-N 5-bromo-2-ethylpyrimidine Chemical compound CCC1=NC=C(Br)C=N1 SQOJDBHJUUGQJP-UHFFFAOYSA-N 0.000 description 3
- NEDJTEXNSTUKHW-UHFFFAOYSA-N 5-bromo-2-methylpyrimidine Chemical compound CC1=NC=C(Br)C=N1 NEDJTEXNSTUKHW-UHFFFAOYSA-N 0.000 description 3
- UDQGIOYIJKRLFH-UHFFFAOYSA-N 5-bromo-n-methylpyrimidin-2-amine Chemical compound CNC1=NC=C(Br)C=N1 UDQGIOYIJKRLFH-UHFFFAOYSA-N 0.000 description 3
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 3
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 125000005217 alkenylheteroaryl group Chemical group 0.000 description 3
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 125000005018 aryl alkenyl group Chemical group 0.000 description 3
- 125000005015 aryl alkynyl group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 3
- 150000003936 benzamides Chemical class 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- QFNOUPAKTVGXKG-RMKNXTFCSA-N ethyl (e)-3-[4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1N(C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 QFNOUPAKTVGXKG-RMKNXTFCSA-N 0.000 description 3
- RIKWUDSTCMHIKH-VMPITWQZSA-N ethyl (e)-3-[4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1NCC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 RIKWUDSTCMHIKH-VMPITWQZSA-N 0.000 description 3
- LPCXIPFIONKCLI-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2-hydroxyethyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCO)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 LPCXIPFIONKCLI-UHFFFAOYSA-N 0.000 description 3
- CACKLWNGDUDAEB-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2-methoxyethyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCOC)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 CACKLWNGDUDAEB-UHFFFAOYSA-N 0.000 description 3
- QGYZVWQCNLRYPQ-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2-methylpropyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 QGYZVWQCNLRYPQ-UHFFFAOYSA-N 0.000 description 3
- BVEZXDLCFBQECW-UHFFFAOYSA-N ethyl 2-[2-hydroxyethyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCO)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 BVEZXDLCFBQECW-UHFFFAOYSA-N 0.000 description 3
- AIYAYPKLVPBNQR-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methoxyethyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCOC)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 AIYAYPKLVPBNQR-UHFFFAOYSA-N 0.000 description 3
- SBLYJKKFSUGBLA-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methylpropyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)C)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SBLYJKKFSUGBLA-UHFFFAOYSA-N 0.000 description 3
- TUVSWNFMUMLSLP-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-propylamino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 TUVSWNFMUMLSLP-UHFFFAOYSA-N 0.000 description 3
- QLMMAQVFJCVMQB-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 QLMMAQVFJCVMQB-UHFFFAOYSA-N 0.000 description 3
- XQJLOCQFVGIVAB-UHFFFAOYSA-N ethyl 2-[[2-(3-aminophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(N)C=CC=3)=NC(N3CCOCC3)=C2S1 XQJLOCQFVGIVAB-UHFFFAOYSA-N 0.000 description 3
- ONZDGTIFPRNBHV-UHFFFAOYSA-N ethyl 2-[[2-(6-fluoro-1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=4C=NNC=4C=C(F)C=3)=NC(N3CCOCC3)=C2S1 ONZDGTIFPRNBHV-UHFFFAOYSA-N 0.000 description 3
- ZMZMEHOHPOEHSR-UHFFFAOYSA-N ethyl 2-[[2-[3-(dimethylamino)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(C=CC=3)N(C)C)=NC(N3CCOCC3)=C2S1 ZMZMEHOHPOEHSR-UHFFFAOYSA-N 0.000 description 3
- TXEYIHWEDAZOBE-UHFFFAOYSA-N ethyl 2-[butyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 TXEYIHWEDAZOBE-UHFFFAOYSA-N 0.000 description 3
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
- XKHBPDUDFXDHBG-UHFFFAOYSA-N ethyl 6-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]hexanoate Chemical compound C=12SC(CN(C)CCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 XKHBPDUDFXDHBG-UHFFFAOYSA-N 0.000 description 3
- OTLZEKFFEVFHSV-UHFFFAOYSA-N ethyl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]hexanoate Chemical compound C=12SC(CN(C)CCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 OTLZEKFFEVFHSV-UHFFFAOYSA-N 0.000 description 3
- DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 3
- XBDOBUVAIHMWEU-UHFFFAOYSA-N ethyl 7-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]heptanoate Chemical compound C=12SC(CN(C)CCCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 XBDOBUVAIHMWEU-UHFFFAOYSA-N 0.000 description 3
- VRFWBAUFHPFHQQ-UHFFFAOYSA-N ethyl 7-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]heptanoate Chemical compound C=12SC(CNCCCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 VRFWBAUFHPFHQQ-UHFFFAOYSA-N 0.000 description 3
- WMCGQYUCWPJPIG-UHFFFAOYSA-N ethyl 7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]heptanoate Chemical compound C=12SC(CN(C)CCCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 WMCGQYUCWPJPIG-UHFFFAOYSA-N 0.000 description 3
- CXJDJFMMCPSTFU-UHFFFAOYSA-N ethyl 7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]heptanoate Chemical compound C=12SC(CNCCCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 CXJDJFMMCPSTFU-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 3
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 3
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- XMXUJDFHPVOABU-UHFFFAOYSA-N methyl 2-[[2-[3-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(CN)C=CC=3)=NC(N3CCOCC3)=C2S1 XMXUJDFHPVOABU-UHFFFAOYSA-N 0.000 description 3
- NNOYNOFEXBGPIU-UHFFFAOYSA-N methyl 2-[[2-[4-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OC)=CN=C1N(C)CC1=CC2=NC(C=3C=CC(CN)=CC=3)=NC(N3CCOCC3)=C2S1 NNOYNOFEXBGPIU-UHFFFAOYSA-N 0.000 description 3
- MYNCNLJWMBYMLQ-UHFFFAOYSA-N methyl 5-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]pentanoate Chemical compound C=12SC(CN(C)CCCCC(=O)OC)=CC2=NC(Cl)=NC=1N1CCOCC1 MYNCNLJWMBYMLQ-UHFFFAOYSA-N 0.000 description 3
- MOCKCAAJZUUZDN-UHFFFAOYSA-N methyl 5-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pentanoate Chemical compound C=12SC(CN(C)CCCCC(=O)OC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 MOCKCAAJZUUZDN-UHFFFAOYSA-N 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 3
- MSLICLMCQYQNPK-UHFFFAOYSA-N n-(4-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C=C1 MSLICLMCQYQNPK-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- ZDQZRIXKDPITGG-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-2-methoxyethanamine Chemical compound C=12SC(CNCCOC)=CC2=NC(Cl)=NC=1N1CCOCC1 ZDQZRIXKDPITGG-UHFFFAOYSA-N 0.000 description 3
- DIYXXWCZYVTSAB-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-2-methylpropan-1-amine Chemical compound C=12SC(CNCC(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 DIYXXWCZYVTSAB-UHFFFAOYSA-N 0.000 description 3
- RUZSAERWZSIPBC-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]butan-1-amine Chemical compound C=12SC(CNCCCC)=CC2=NC(Cl)=NC=1N1CCOCC1 RUZSAERWZSIPBC-UHFFFAOYSA-N 0.000 description 3
- UVPIDNMBEZYIIU-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(Br)=C1 UVPIDNMBEZYIIU-UHFFFAOYSA-N 0.000 description 3
- HBBBWKUVJSIFKV-UHFFFAOYSA-N n-[(4-bromophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=C(Br)C=C1 HBBBWKUVJSIFKV-UHFFFAOYSA-N 0.000 description 3
- PQDVDZVHXAMKJG-UHFFFAOYSA-N n-hydroxy-2-[2-hydroxyethyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCO)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 PQDVDZVHXAMKJG-UHFFFAOYSA-N 0.000 description 3
- MNKGAFXPZNKRLL-UHFFFAOYSA-N n-hydroxy-2-[methyl-[(4-morpholin-4-yl-2-pyrimidin-5-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC=NC=1)=NC=2N1CCOCC1 MNKGAFXPZNKRLL-UHFFFAOYSA-N 0.000 description 3
- KPWICCCSPDNTKF-UHFFFAOYSA-N n-hydroxy-6-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]hexanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C4=CN(CCCCCC(=O)NO)N=C4C=CC=3)=NC(N3CCOCC3)=C2S1 KPWICCCSPDNTKF-UHFFFAOYSA-N 0.000 description 3
- FKEFYPSFROAUKX-UHFFFAOYSA-N n-hydroxy-7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]heptanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C4=CN(CCCCCCC(=O)NO)N=C4C=CC=3)=NC(N3CCOCC3)=C2S1 FKEFYPSFROAUKX-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000011581 secondary neoplasm Diseases 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960003010 sodium sulfate Drugs 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- FSWNRRSWFBXQCL-UHFFFAOYSA-N (3-bromophenyl)methanol Chemical compound OCC1=CC=CC(Br)=C1 FSWNRRSWFBXQCL-UHFFFAOYSA-N 0.000 description 2
- NCNYEGJDGNOYJX-NSCUHMNNSA-N (e)-2,3-dibromo-4-oxobut-2-enoic acid Chemical compound OC(=O)C(\Br)=C(/Br)C=O NCNYEGJDGNOYJX-NSCUHMNNSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- GJWKKAKHLVXWOC-UHFFFAOYSA-N 2-(1-anilinoethyl)chromen-4-one Chemical compound C1(=CC=CC=C1)NC(C)C=1OC2=C(C(C1)=O)C=CC=C2 GJWKKAKHLVXWOC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OXVNXMRYVMCDCA-UHFFFAOYSA-N 2-[2,2-dimethylpropyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CC(C)(C)C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 OXVNXMRYVMCDCA-UHFFFAOYSA-N 0.000 description 2
- ZIPBZSLLZVMHDP-UHFFFAOYSA-N 2-[[2-(2-aminopyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC(N)=NC=1)=NC=2N1CCOCC1 ZIPBZSLLZVMHDP-UHFFFAOYSA-N 0.000 description 2
- BWJXAMWLLOJJEN-UHFFFAOYSA-N 2-[[2-(4-aminophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(N)=CC=1)=NC=2N1CCOCC1 BWJXAMWLLOJJEN-UHFFFAOYSA-N 0.000 description 2
- RQZWOUUGADXLAW-UHFFFAOYSA-N 2-[[2-(6-fluoro-1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=C(F)C=1)=NC=2N1CCOCC1 RQZWOUUGADXLAW-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- IILVSKMKMOJHMA-UHFFFAOYSA-N 3-bromo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1Br IILVSKMKMOJHMA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- GPIJEJLGYBWEGA-UHFFFAOYSA-N 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]butanoic acid Chemical compound C=12SC(CNCCCC(=O)O)=CC2=NC(Cl)=NC=1N1CCOCC1 GPIJEJLGYBWEGA-UHFFFAOYSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- FTBWYCGHGSATOE-UHFFFAOYSA-N 5-bromo-2-ethylpyrimidine-4-carboxylic acid Chemical compound CCC1=NC=C(Br)C(C(O)=O)=N1 FTBWYCGHGSATOE-UHFFFAOYSA-N 0.000 description 2
- MDERWSRHRJUWNS-UHFFFAOYSA-N 5-bromo-2-methylpyrimidine-4-carboxylic acid Chemical compound CC1=NC=C(Br)C(C(O)=O)=N1 MDERWSRHRJUWNS-UHFFFAOYSA-N 0.000 description 2
- LPQVTZJEIXYDQA-UHFFFAOYSA-N 5-bromo-4-methylpyrimidin-2-amine Chemical compound CC1=NC(N)=NC=C1Br LPQVTZJEIXYDQA-UHFFFAOYSA-N 0.000 description 2
- NUFQTVKZZVRLAW-UHFFFAOYSA-N 8-(2-fluorophenyl)-2-morpholin-4-yl-1h-quinolin-4-one Chemical compound FC1=CC=CC=C1C1=CC=CC2=C1NC(N1CCOCC1)=CC2=O NUFQTVKZZVRLAW-UHFFFAOYSA-N 0.000 description 2
- VWUOLZVKYIOWMD-UHFFFAOYSA-N 8-(3-chlorophenoxy)-2-morpholin-4-ylchromen-4-one Chemical compound ClC1=CC=CC(OC=2C3=C(C(C=C(O3)N3CCOCC3)=O)C=CC=2)=C1 VWUOLZVKYIOWMD-UHFFFAOYSA-N 0.000 description 2
- CKWLQQYSUOHSHB-UHFFFAOYSA-N 8-(benzylamino)-2-morpholin-4-ylchromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1NCC1=CC=CC=C1 CKWLQQYSUOHSHB-UHFFFAOYSA-N 0.000 description 2
- BBPLUKPNVSISTA-UHFFFAOYSA-N 8-anilino-2-morpholin-4-ylchromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1NC1=CC=CC=C1 BBPLUKPNVSISTA-UHFFFAOYSA-N 0.000 description 2
- XNDOAFNGHIXHPI-UHFFFAOYSA-N 8-benzyl-2-morpholin-4-ylchromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1CC1=CC=CC=C1 XNDOAFNGHIXHPI-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 2
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229940054066 benzamide antipsychotics Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- DNQDFYFSMYUFMU-FMIVXFBMSA-N ethyl (e)-3-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1N(C)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 DNQDFYFSMYUFMU-FMIVXFBMSA-N 0.000 description 2
- GKYHPORUOQSVBH-UHFFFAOYSA-N ethyl 2-[4-[[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CNCC=2SC3=C(N4CCOCC4)N=C(Cl)N=C3C=2)CC1 GKYHPORUOQSVBH-UHFFFAOYSA-N 0.000 description 2
- FAUKJUCTMOIXNO-UHFFFAOYSA-N ethyl 2-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 FAUKJUCTMOIXNO-UHFFFAOYSA-N 0.000 description 2
- SUMIVCXBRSWABL-UHFFFAOYSA-N ethyl 2-[4-[[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CNCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 SUMIVCXBRSWABL-UHFFFAOYSA-N 0.000 description 2
- MRROIODOELYXLL-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MRROIODOELYXLL-UHFFFAOYSA-N 0.000 description 2
- UNNWRXRVNQNALM-UHFFFAOYSA-N ethyl 2-[[2-(2-amino-4-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C(=NC(N)=NC=3)C)=NC(N3CCOCC3)=C2S1 UNNWRXRVNQNALM-UHFFFAOYSA-N 0.000 description 2
- HXZNQJDNUWCJHY-UHFFFAOYSA-N ethyl 2-[[2-(2-aminopyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 HXZNQJDNUWCJHY-UHFFFAOYSA-N 0.000 description 2
- MIGWJYBFTLKLOL-UHFFFAOYSA-N ethyl 2-[[2-(2-ethylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(CC)=NC=3)=NC(N3CCOCC3)=C2S1 MIGWJYBFTLKLOL-UHFFFAOYSA-N 0.000 description 2
- XJFCHPBHAATVLP-UHFFFAOYSA-N ethyl 2-[[2-(3-carbamoylphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(C=CC=3)C(N)=O)=NC(N3CCOCC3)=C2S1 XJFCHPBHAATVLP-UHFFFAOYSA-N 0.000 description 2
- XQGYOWDOXLWEFO-UHFFFAOYSA-N ethyl 2-[[2-(3-hydroxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(O)C=CC=3)=NC(N3CCOCC3)=C2S1 XQGYOWDOXLWEFO-UHFFFAOYSA-N 0.000 description 2
- SPCKLCJFCNDNIB-UHFFFAOYSA-N ethyl 2-[[2-(3-methoxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(OC)C=CC=3)=NC(N3CCOCC3)=C2S1 SPCKLCJFCNDNIB-UHFFFAOYSA-N 0.000 description 2
- GDDXVQISIJHIDV-UHFFFAOYSA-N ethyl 2-[[2-(4-acetamidophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=CC(NC(C)=O)=CC=3)=NC(N3CCOCC3)=C2S1 GDDXVQISIJHIDV-UHFFFAOYSA-N 0.000 description 2
- VFHBISXAIQCGSQ-UHFFFAOYSA-N ethyl 2-[[2-(6-aminopyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(N)=CC=3)=NC(N3CCOCC3)=C2S1 VFHBISXAIQCGSQ-UHFFFAOYSA-N 0.000 description 2
- YXCLUYNNGQVPNJ-UHFFFAOYSA-N ethyl 2-[[2-[2-(dimethylamino)pyrimidin-5-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(=NC=3)N(C)C)=NC(N3CCOCC3)=C2S1 YXCLUYNNGQVPNJ-UHFFFAOYSA-N 0.000 description 2
- MKVSOTQWUZQPFX-UHFFFAOYSA-N ethyl 2-[[2-[2-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C(=CC=CC=3)CO)=NC(N3CCOCC3)=C2S1 MKVSOTQWUZQPFX-UHFFFAOYSA-N 0.000 description 2
- FUKSLNAEIGFUIE-UHFFFAOYSA-N ethyl 2-[[2-[3-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(CO)C=CC=3)=NC(N3CCOCC3)=C2S1 FUKSLNAEIGFUIE-UHFFFAOYSA-N 0.000 description 2
- WHAWZNUURUQDAP-UHFFFAOYSA-N ethyl 2-[[2-[4-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=CC(CO)=CC=3)=NC(N3CCOCC3)=C2S1 WHAWZNUURUQDAP-UHFFFAOYSA-N 0.000 description 2
- PMDDZTZMZLEPHK-UHFFFAOYSA-N ethyl 2-[methyl-[(4-morpholin-4-yl-2-pyridin-3-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC=CC=3)=NC(N3CCOCC3)=C2S1 PMDDZTZMZLEPHK-UHFFFAOYSA-N 0.000 description 2
- OCUBOOXWTKHWQL-UHFFFAOYSA-N ethyl 2-[methyl-[(4-morpholin-4-yl-2-pyrimidin-5-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC=NC=3)=NC(N3CCOCC3)=C2S1 OCUBOOXWTKHWQL-UHFFFAOYSA-N 0.000 description 2
- BKQQNTZRYZEKOQ-UHFFFAOYSA-N ethyl 2-[methyl-[[2-(2-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(C)=NC=3)=NC(N3CCOCC3)=C2S1 BKQQNTZRYZEKOQ-UHFFFAOYSA-N 0.000 description 2
- IMQIXYSBCZEWCP-UHFFFAOYSA-N ethyl 2-[methyl-[[2-[2-(methylamino)pyrimidin-5-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(NC)=NC=3)=NC(N3CCOCC3)=C2S1 IMQIXYSBCZEWCP-UHFFFAOYSA-N 0.000 description 2
- IDEVQOIRXCUBOD-UHFFFAOYSA-N ethyl 2-[methyl-[[2-[3-(methylcarbamoyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(C=CC=3)C(=O)NC)=NC(N3CCOCC3)=C2S1 IDEVQOIRXCUBOD-UHFFFAOYSA-N 0.000 description 2
- BZOOUMSCSPSRRF-UHFFFAOYSA-N ethyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NCC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BZOOUMSCSPSRRF-UHFFFAOYSA-N 0.000 description 2
- ACIZUJVIZDHCNZ-UHFFFAOYSA-N ethyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]butanoate Chemical compound C=12SC(CNCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 ACIZUJVIZDHCNZ-UHFFFAOYSA-N 0.000 description 2
- MCHVFQATGDYRLZ-UHFFFAOYSA-N ethyl 4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MCHVFQATGDYRLZ-UHFFFAOYSA-N 0.000 description 2
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 2
- BOWFAHZTARBHQD-UHFFFAOYSA-N ethyl 7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]heptanoate Chemical compound C=1C=CC2=NN(CCCCCCC(=O)OCC)C=C2C=1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 BOWFAHZTARBHQD-UHFFFAOYSA-N 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PKDBSOOYVOEUQR-UHFFFAOYSA-N mucobromic acid Natural products OC1OC(=O)C(Br)=C1Br PKDBSOOYVOEUQR-UHFFFAOYSA-N 0.000 description 2
- ATYRNODNUVIWBG-UHFFFAOYSA-N n-hydroxy-2-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 ATYRNODNUVIWBG-UHFFFAOYSA-N 0.000 description 2
- GXYREYVTSFNGJF-UHFFFAOYSA-N n-hydroxy-2-[4-[[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CN(C)CC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 GXYREYVTSFNGJF-UHFFFAOYSA-N 0.000 description 2
- XONGAZPJJPHEKC-UHFFFAOYSA-N n-hydroxy-2-[4-[[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCC(CNCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 XONGAZPJJPHEKC-UHFFFAOYSA-N 0.000 description 2
- VMBXUSDSCBFZLJ-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 VMBXUSDSCBFZLJ-UHFFFAOYSA-N 0.000 description 2
- IEHFCERFRUFCDV-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-propylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 IEHFCERFRUFCDV-UHFFFAOYSA-N 0.000 description 2
- QBBYRWAXWMJNNO-UHFFFAOYSA-N n-hydroxy-2-[methyl-[[2-[2-(methylamino)pyrimidin-5-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound C1=NC(NC)=NC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 QBBYRWAXWMJNNO-UHFFFAOYSA-N 0.000 description 2
- DSMDDAAMHVAWTG-UHFFFAOYSA-N n-hydroxy-4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]butanamide Chemical compound C=12SC(CN(CCCC(=O)NO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 DSMDDAAMHVAWTG-UHFFFAOYSA-N 0.000 description 2
- YNWYTDNDNHEVSO-UHFFFAOYSA-N n-hydroxy-4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]butanamide Chemical compound C=12SC(CNCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YNWYTDNDNHEVSO-UHFFFAOYSA-N 0.000 description 2
- NMCVAWFPRVBSQC-UHFFFAOYSA-N n-hydroxy-6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)NO)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 NMCVAWFPRVBSQC-UHFFFAOYSA-N 0.000 description 2
- WAGWMOSMPPGBDC-UHFFFAOYSA-N n-hydroxy-7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]heptanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NN(CCCCCCC(=O)NO)C=4C=CC=3)=NC(N3CCOCC3)=C2S1 WAGWMOSMPPGBDC-UHFFFAOYSA-N 0.000 description 2
- FFUNNUWCOYEYHG-UHFFFAOYSA-N n-hydroxy-7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]heptanamide Chemical compound C=12SC(CNCCCCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FFUNNUWCOYEYHG-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000006548 oncogenic transformation Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- DFWRZHZPJJAJMX-UHFFFAOYSA-N propanimidamide;hydrochloride Chemical compound Cl.CCC(N)=N DFWRZHZPJJAJMX-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- IOWGHQGLUMEZKG-UHFFFAOYSA-N (2-bromophenyl)methanol Chemical compound OCC1=CC=CC=C1Br IOWGHQGLUMEZKG-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- UGEQUCUBWNAUJS-UHFFFAOYSA-N (3-bromophenyl)methanamine;hydrochloride Chemical compound Cl.NCC1=CC=CC(Br)=C1 UGEQUCUBWNAUJS-UHFFFAOYSA-N 0.000 description 1
- XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- WKJOQYHMXRVQDK-UHFFFAOYSA-N 2-(dimethylamino)acetamide Chemical compound CN(C)CC(N)=O WKJOQYHMXRVQDK-UHFFFAOYSA-N 0.000 description 1
- GHCFWKFREBNSPC-UHFFFAOYSA-N 2-Amino-4-methylpyrimidine Chemical compound CC1=CC=NC(N)=N1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 1
- YUARZLJFVKGLFC-UHFFFAOYSA-N 2-[6-[(6-fluoroquinolin-2-yl)methylamino]-3-bicyclo[3.1.0]hexanyl]-n-hydroxypyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1C1CC(C2NCC=3N=C4C=CC(F)=CC4=CC=3)C2C1 YUARZLJFVKGLFC-UHFFFAOYSA-N 0.000 description 1
- WDLHFHCVMWJNOG-UHFFFAOYSA-N 2-[[2-[4-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylic acid Chemical compound N=1C=C(C(O)=O)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(CN)=CC=1)=NC=2N1CCOCC1 WDLHFHCVMWJNOG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- FBZSEJLLDVYGSZ-UHFFFAOYSA-N 2-morpholin-4-yl-8-phenylmethoxychromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1OCC1=CC=CC=C1 FBZSEJLLDVYGSZ-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- PBOOZQFGWNZNQE-UHFFFAOYSA-N 3-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Br)=C1 PBOOZQFGWNZNQE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- MXWDSZWTBOCWBK-UHFFFAOYSA-N 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Chemical compound CN(C)C1=CC=C(C(=O)NCCCCCCC(=O)NO)C=C1 MXWDSZWTBOCWBK-UHFFFAOYSA-N 0.000 description 1
- DDGJOTNSVPHXNT-UHFFFAOYSA-N 4-[6-(bromomethyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(CBr)=CC2=NC(Cl)=NC=1N1CCOCC1 DDGJOTNSVPHXNT-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SKWTUNAAJNDEIK-UHFFFAOYSA-N 4-fluoro-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(F)C=C1[N+]([O-])=O SKWTUNAAJNDEIK-UHFFFAOYSA-N 0.000 description 1
- BLOIUFYKQCCAGP-UHFFFAOYSA-N 5-aminopentanoic acid;hydron;chloride Chemical compound Cl.NCCCCC(O)=O BLOIUFYKQCCAGP-UHFFFAOYSA-N 0.000 description 1
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
- UHRHPPKWXSNZLR-UHFFFAOYSA-N 5-bromopyrimidin-2-amine Chemical compound NC1=NC=C(Br)C=N1 UHRHPPKWXSNZLR-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RMYDYIDGGSILID-UHFFFAOYSA-N 7-aminoheptanoic acid;hydrochloride Chemical compound Cl.NCCCCCCC(O)=O RMYDYIDGGSILID-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- MHFWTFWRBOGPGH-UHFFFAOYSA-N 8-(3-methylphenyl)-2-morpholin-4-yl-1h-quinolin-4-one Chemical compound CC1=CC=CC(C=2C3=C(C(C=C(N3)N3CCOCC3)=O)C=CC=2)=C1 MHFWTFWRBOGPGH-UHFFFAOYSA-N 0.000 description 1
- BWTPNSFEPOGLDT-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenoxy)-2-morpholin-4-ylchromen-4-one Chemical compound CC1=CC(F)=CC=C1OC1=CC=CC2=C1OC(N1CCOCC1)=CC2=O BWTPNSFEPOGLDT-UHFFFAOYSA-N 0.000 description 1
- LLVIJSKMPLJKKS-UHFFFAOYSA-N 8-(4-fluorophenoxy)-2-morpholin-4-yl-1h-quinolin-4-one Chemical compound C1=CC(F)=CC=C1OC1=CC=CC2=C1NC(N1CCOCC1)=CC2=O LLVIJSKMPLJKKS-UHFFFAOYSA-N 0.000 description 1
- UBJVUQITODDUCW-UHFFFAOYSA-N 9-(benzylamino)-7-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C12=NC(N3CCOCC3)=CC(=O)N2C=C(C)C=C1NCC1=CC=CC=C1 UBJVUQITODDUCW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 101100123574 Arabidopsis thaliana HDA19 gene Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101150083200 HDA1 gene Proteins 0.000 description 1
- 108091005772 HDAC11 Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 1
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010033104 M-81 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101100297422 Schizosaccharomyces pombe (strain 972 / ATCC 24843) phd1 gene Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- CHIWXYAWZYPFJS-UHFFFAOYSA-N bromomethoxybenzene Chemical compound BrCOC1=CC=CC=C1 CHIWXYAWZYPFJS-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- NRPMBSHHBFFYBF-VMPITWQZSA-N ethyl (e)-3-(4-aminophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(N)C=C1 NRPMBSHHBFFYBF-VMPITWQZSA-N 0.000 description 1
- FQBWWPNSVVYCHN-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 FQBWWPNSVVYCHN-UHFFFAOYSA-N 0.000 description 1
- AGQYZUBSUHPUES-UHFFFAOYSA-N ethyl 2-[4-(aminomethyl)piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CN)CC1 AGQYZUBSUHPUES-UHFFFAOYSA-N 0.000 description 1
- YXSRBUNPFJSJMO-UHFFFAOYSA-N ethyl 2-[4-[[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CN(C)CC=2SC3=C(N4CCOCC4)N=C(Cl)N=C3C=2)CC1 YXSRBUNPFJSJMO-UHFFFAOYSA-N 0.000 description 1
- PAPJBLRHKZTQCI-UHFFFAOYSA-N ethyl 2-[4-[[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CN(C)CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 PAPJBLRHKZTQCI-UHFFFAOYSA-N 0.000 description 1
- IICYSWWKXZIEER-UHFFFAOYSA-N ethyl 2-[[2-(4-aminophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=CC(N)=CC=3)=NC(N3CCOCC3)=C2S1 IICYSWWKXZIEER-UHFFFAOYSA-N 0.000 description 1
- YONDQZJYPVGDSZ-UHFFFAOYSA-N ethyl 2-[[2-[3-(methoxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(COC)C=CC=3)=NC(N3CCOCC3)=C2S1 YONDQZJYPVGDSZ-UHFFFAOYSA-N 0.000 description 1
- UDVBSJWIOXLCBG-UHFFFAOYSA-N ethyl 2-[butyl-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCCC)CC(SC1=2)=CC1=NC(Cl)=NC=2N1CCOCC1 UDVBSJWIOXLCBG-UHFFFAOYSA-N 0.000 description 1
- BHXIWUJLHYHGSJ-UHFFFAOYSA-N ethyl 3-ethoxypropanoate Chemical compound CCOCCC(=O)OCC BHXIWUJLHYHGSJ-UHFFFAOYSA-N 0.000 description 1
- BJOXQFPCSUMLQN-UHFFFAOYSA-N ethyl 4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoate Chemical compound C=12SC(CN(CCCC(=O)OCC)C(=O)OC(C)(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 BJOXQFPCSUMLQN-UHFFFAOYSA-N 0.000 description 1
- CXVQSUBJMYZELD-UHFFFAOYSA-N ethyl 4-aminobutanoate;hydrochloride Chemical compound [Cl-].CCOC(=O)CCC[NH3+] CXVQSUBJMYZELD-UHFFFAOYSA-N 0.000 description 1
- MMSVBKQTXSDWQN-UHFFFAOYSA-N ethyl 6-aminohexanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCCCCN MMSVBKQTXSDWQN-UHFFFAOYSA-N 0.000 description 1
- FIKVWPJKNMTBBD-UHFFFAOYSA-N ethyl 6-aminopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(N)N=C1 FIKVWPJKNMTBBD-UHFFFAOYSA-N 0.000 description 1
- OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MWKNNKYCIOCAJW-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MWKNNKYCIOCAJW-UHFFFAOYSA-N 0.000 description 1
- MRTLGVFZAYBGEY-UHFFFAOYSA-N n-hydroxy-2-[[2-[3-(methoxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound COCC1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 MRTLGVFZAYBGEY-UHFFFAOYSA-N 0.000 description 1
- PZCFAXKRBOEWTP-UHFFFAOYSA-N n-hydroxy-5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]pentanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NN(CCCCC(=O)NO)C=4C=CC=3)=NC(N3CCOCC3)=C2S1 PZCFAXKRBOEWTP-UHFFFAOYSA-N 0.000 description 1
- RXTBFCCUFLHJJU-UHFFFAOYSA-N n-hydroxy-5-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pentanamide Chemical compound C=12SC(CNCCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 RXTBFCCUFLHJJU-UHFFFAOYSA-N 0.000 description 1
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- VEDDBHYQWFOITD-UHFFFAOYSA-N para-bromobenzyl alcohol Chemical compound OCC1=CC=C(Br)C=C1 VEDDBHYQWFOITD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- AEABQBMUYZBBCW-UHFFFAOYSA-N pentanamide Chemical compound CC[CH]CC(N)=O AEABQBMUYZBBCW-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- JUDRXQZHONTBBN-UHFFFAOYSA-N propan-2-yl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC(C)C)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 JUDRXQZHONTBBN-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- FXJZOUPFQNMFOR-UHFFFAOYSA-N pyrimidin-2-ylboronic acid Chemical compound OB(O)C1=NC=CC=N1 FXJZOUPFQNMFOR-UHFFFAOYSA-N 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229950010654 quisinostat Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
- XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DXJJURFOCLURRH-UHFFFAOYSA-N tert-butyl n-[4-(hydroxyamino)-4-oxobutyl]-n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]carbamate Chemical compound C=12SC(CN(CCCC(=O)NO)C(=O)OC(C)(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 DXJJURFOCLURRH-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the members of the ras gene family encode membrane-bound proteins of about 21 kD which are referred to as p21-ras. These proteins are believed to relay growth and differentiation signals from activated receptors to intracellular protein kinases.
- the ras gene family includes K-ras, H-ras and N-ras.
- the ras genes are proto-oncogenes; mutated ras genes are found in a variety of cancer types. These mutants typically exhibit a single base pair substitution, usually in codon 12, 13, 146 or 161, which leads to an expressed p21-ras product with a point mutation at the corresponding amino acid position.
- codon 12 codes for glycine, but in the most common mutations this codon codes for aspartic acid, valine, arginine or cysteine (Mu et al., World J. Gastroenterol. 2004, 10: 471-475). While wild-type p21-ras is activated only by an activated receptor and deactivated after downstream signaling, the p21-ras mutants are constitutively active, and thus stimulate growth and differentiation continuously, in the absence of a signal (Bos, J.L., Cancer Res. 1989, 49: 4682-4689).
- K-ras mutations occur in variety of cancers.
- K-ras mutations are prevalent in pancreatic, colorectal, thyroid, lung, cervical and endometrial cancer.
- K- ras mutations have also been identified in certain precancerous conditions, such as myelodysplasia syndrome and adenomas of the thyroid and the colon.
- the present invention provides methods and compositions for treating cancers and precancerous conditions which are characterized by proliferating cells having a K-ras mutation.
- the invention provides a method of inhibiting the proliferation of cells having a K-ras mutation, such as pre-cancerous cells or cancer cells.
- the method comprises the steps of (1) identifying cells which have a K-ras mutation; (2) inhibiting the PI3 kinase signaling pathway in the cells; and (3) inhibiting HDAC activity in the cells.
- the PI3 kinase signaling pathway and HDAC activity are inhibited by contacting the cells with a first compound which inhibits PI3 kinase activity and a second compound which inhibits HDAC activity.
- the PI3 kinase signaling pathway and HDAC activity are inhibited by contacting the cells with a compound which inhibits both PI3 kinase activity and HDAC activity.
- the invention provides a method of treating cancer or a precancerous condition associated with a K-ras mutation in a subject in need thereof.
- the method comprises the steps of (1) identifying a subject having a cancer or a precancerous condition associated with a K-ras mutation; (2) administering to the subject (i) an amount of a PI3 kinase inhibitor and (ii) an amount of an HDAC inhibitor, where the amount of a compound which inhibits PI3 kinase and the amount of a compound which inhibits HDAC together are therapeutically effective.
- the PI3 kinase inhibitor and the HDAC inhibitor can be administered simultaneously or sequentially and as separate compositions or combined in a single composition.
- the invention provides a method of treating a cancer or a precancerous condition associated with mutated K-ras in a subject in need thereof.
- the method comprises the steps of (1) identifying a subject having a cancer or precancerous condition associated with a K-ras mutation; (2) administering to the subject an effective amount of a compound is a PI3 kinase inhibitor and an HDAC inhibitor.
- the invention additionally includes compounds and compositions for use in the disclosed methods.
- Phosphoinositides which are phosphorylated derivatives of
- PI3-kinases phosphorylate
- Phosphorylated PKB inhibits apoptosis-inducing proteins such as FKHR, Bad, and caspases, and is thought to play an important role in cancer progression.
- the PBKs are divided into classes I-III, and class I is further subclassified into classes la and lb.
- class la enzymes are thought to play the most important role in cell proliferation in response to growth factor-tyrosine kinase pathway activation (Hayakawa et. al, Bioorganic & Medicinal Chemistry 14 6847-6858, 2006).
- Three frequent mutations in cancer constitutively activate PBKa and, when expressed in cells, they drive the oncogenic transformation and chronic activation of downstream signalling by molecules such as PKB, S6K and 4E bpl that is commonly seen in cancer cells. (Stephens et. al., Current Opinion in Pharmacology, 5(4) 357-365, 2005). As such, PI3-kinases are attractive targets for the treatment of proliferative diseases.
- PI3 -kinase inhibitors There are several known PI3 -kinase inhibitors including Wortmannin and
- wortmannin is a potent PI3K inhibitor with a low nanomolar IC 50 value, it has low in vivo anti-tumor activity. (Hayakawa et al, Bioorg Med Chem 14(20), 6847-6858 (2006)). Recently, a group of morpholine substituted quinazoline,
- pyridopyrimidine and thienopyrimidine compounds have been reported to be effective in inhibiting PBkinase pi 10a.
- Oral dosage of a morpholine substituted thienopyrimidine compound has shown tumor suppression in glioblastoma xenografts in vivo.
- the following publications disclose a series of thienopyrimidine,
- pyridopyrimidine and quinazoline based PI3-Kinase inhibitors WO 2008/073785; WO 2008/070740; WO 2007/127183; U.S. Patent Publication 20080242665.
- Histone acetylation is a reversible modification, with deacetylation being catalyzed by a family of enzymes termed histone deacetylases (HDACs).
- HDAC's are represented by 18 genes in humans and are divided into four distinct classes (JMol Biol, 2004, 338: 1, 17- 31).
- class I HDAC's HDACl-3, and HDAC8 are related to yeast RPD3 HDAC
- class 2 HDAC4-7, HDAC9 and HDAC10 related to yeast HDA1
- HDAC11 HDAC11
- class 3 a distinct class encompassing the sirtuins which are related to yeast Sir2.
- Csordas Biochem. J, 1990, 286: 23-38 teaches that histones are subject to post- translational acetylation of the, ⁇ -amino groups of N-terminal lysine residues, a reaction that is catalyzed by histone acetyl transferase (HATl).
- HATl histone acetyl transferase
- Acetylation neutralizes the positive charge of the lysine side chain, and is thought to impact chromatin structure.
- access of transcription factors to chromatin templates is enhanced by histone hyperacetylation, and enrichment in underacetylated histone H4 has been found in transcriptionally silent regions of the genome (Taunton et al., Science, 1996, 272:408-411).
- transcriptional silencing due to histone modification can lead to oncogenic transformation and cancer.
- HDAC inhibitors include hydroxamic acid derivatives, Suberoylanilide hydroxamic acid (SAHA), PXD101 and LAQ824, are currently in the clinical development.
- SAHA Suberoylanilide hydroxamic acid
- benzamide MS-275, MGCD0103 and CI-994 have reached clinical trials. Mourne et al. (Abstract #4725, AACR 2005), demonstrate that thiophenyl modification of benzamides significantly enhance HDAC inhibitory activity against HDAC 1.
- the present invention provides methods for treating cancers and precancerous conditions associated with mutated K-ras.
- the invention relates to the discovery that such cancers are particularly susceptible to the effects of concomitant inhibition of PI3 kinase and HDAC.
- the invention provides a method of treating a cancer comprising cancer cells having a K-ras mutation comprising the step of concurrently inhibiting PI3 kinase activity and inhibiting HDAC activity within said the cancer cells.
- a cancer cell or cells associated with a precancerous condition are said to have a mutated K-ras gene if the gene for K-ras within the cell has been mutated relative to the corresponding wild type gene in such a way as to produce a gene product having an amino acid sequence which differs from that of the wild-type K-ras protein.
- the mutated gene has one or more nucleotide sunbstitutions in one or more codons and encodes a protein having one or more point mutations relative to the wild type protein. More preferably, the mutation is in a single codon of the K-ras gene, such as codon 12, 13 or 16. Most preferably the mutation is in codon 12 or 13.
- a subject has a cancer or a precancerous condition is "associated with mutated K-ras" if cells obtained from the subject have a mutated K-ras gene.
- the identification of a K-ras mutation is within the skill in the art, and in one embodiment is done using, for example, methods disclosed herein or other methods as are known in the art.
- the subject is identified as having a cancer associated with mutated K-ras if the subject is diagnosed with a cancer type which with a high probability of mutated K-ras, including pancreatic cancer, such as pancreatic adenocarcinoma, or adenocarcinoma of the colon or lung.
- a K-ras mutation can be identified using methods known in the art. For example, cells from a tumor biopsy, such as a surgical biopsy or a needle aspirate, can be analyzed for the presence of a mutation. The cells can also be obtained from a body fluid, such as blood or urine, or from a stool sample. Methods for detecting K-ras mutations are known in the art and include, but are not limited to, those set forth in Poehlmann, A. et al, Pathol. Res. Pract. 2007, 203: 489-497; van Heek, N.T. et al., J. Clin. Pathol. 2005, 58, 1315- 1320; Taback, B. et al., Int. J.
- Cancers which can be associated with mutated K-ras include pancreatic cancer , such as adenocarcinoma of the pancreas, including ductal adenocarcinoma; lung cancer, such as non-small cell lung cancer and lung adenocarcinoma; colorectal cancer, such as adenocarcinoma of the colon; thyroid cancer, such as follicular carcinoma, undifferentiated carcinoma, and papillary carcinoma; testicular cancer, such as seminoma; leukemia, such as acute myologenous leukemia, chronic myologenous leukemia, multiple myeloma and acute lymphocytic leukemia; multiple myeloma, liver cancer, breast cancer, prostate cancer, ovarian cancer and endometrial cancer.
- pancreatic cancer such as adenocarcinoma of the pancreas, including ductal adenocarcinoma
- lung cancer such as non-small cell lung cancer and lung adenocar
- Non-cancerous conditions which can be associated with mutated K-ras include adenomas, such as colon adenomas and thyroid adenomas, and myelodysplastic syndrome.
- a subject is determined to have a cancer associated with a K-ras mutation if the subject is diagnosed as having a cancer in which the prevalence of K-ras mutation is greater than about 50%.
- cancers include pancreatic cancer, such as ductal adenocarcinoma, which is the cancer type with the highest rate of K-ras mutation.
- Such a cancer is significantly more likely than not to be associated with mutated K-ras, and a clinician may determine that treatment with an inhibitor of PI3 kinase and an inhibitor of HDAC according to the invention is warranted on the basis of the diagnosis of pancreatic cancer, such as ductal adenocarcinoma, without the need for additional testing to confirm the presence of a K-ras mutation.
- PI3 kinase inhibitor is a compound which inhibits cellular signaling through the PI3K/AKT signaling pathway.
- the PI3 kinase inhibitor can be, for example, an inhibitor of one or more proteins involved in this signaling pathway, including PI3 kinase, such as ⁇ , ⁇ , ⁇ , and PI3k5, PKB (AKT), mammmalian Target of Rapamycin ("mTOR”) and/or another protein in the pathway.
- Methods for assessing the ability of a compound to inhibit such proteins include those set forth herein and others known in the art.
- the PB kinase inhibitor is selected from LY294002 (Eli Lily), Wortmannin, Wortmannin analogues, pegylated Wortmannin, pegylated 17-hydroxy-Wortmannin, PX-866, SF1124 (Semafore Pharmaceuticals), SF1126 (Semafore Pharmaceuticals), BEZ235 (Novartis), BGT226 (Novartis), BKM120 (Novartis), XL-765 (Exelexis), XL- 147 (Exelexis), GDC-0941 (Genentech), AS-252424, ONC-201 (Oncalis), CAL-101 (Calistoga), CAL-263 (Calistoga), Atu-027, PF-4691502, PBI-05204 (Phoenix Biotechnology), GSK-2126458, PIK-90, PIK-75, PI-103, ZSTK-474, TGX115, TGX-221 and
- the PB kinase inhibitor is selected from the compounds set forth below:
- a]pyrimidin-4-one (TGX- 137); 7-methyl-2-(4-morpholinyl)-9-[(phenylmethyl)amino]-4H- pyrido[l ,2-a]pyrimidin-4-one (TGX-126); 9-[[(4-fluoro-2-methylphenyl)amino]-7-methyl- 2-(4-morpholinyl)-4H-pyrido[l- ,2-a]pyrimidin-4-one (TGX- 170); 7-methyl-2-(4- morpholinyl)-9-[[(lR)-l-phenylethyl] amino] -4H-pyrido[l,2-a]pyrimidin-4-one (TGX- 123); 7-methyl-2-(4-morpholinyl)-9-[(2-pyridinylmethyl)amino]-4H-pyrido[l,2-a]pyrim one (TGX-161); 9-[[[(4-chloroph
- (+/-)-7-methyl-9- [ 1 -(3 -methylphenylamino)ethyl]-2-morpholin-4-yl-pyrido [ 1 ,2- a]pyrimidin-4-one (TGX-262); (+/-)-7-methyl-2-morpholin-4-yl-9-[l-(3- trifluoromethylphenylamino)ethyl]- -pyrido[l,2-a]pyrimidin-4-one (TGX-264); (+/-)-7- methyl-2-morpholin-4-yl-9-[l-(2-pyridinylamino)ethyl]-pyrido[l,2-a]pyrimidin-4-one (TGX-295); (+/-)-2-( ⁇ 1 7-methyl-2-(morpholin4-yl)-4-oxo-pyrido[l,2-a]pyrimidin-9-yl- ]ethyl ⁇ amino)benzoic acid (K -309);
- (+/-) methyl 2-( ⁇ l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[l,2-a]pyrimidin-9-yl]ethy- 1 ⁇ amino)benzoate K -321
- (+/-)-2-( ⁇ 1 -[7-methyl-2-(morpholi-4-yl)-4-oxo-pyrido[l ,2- a]pyrimidin-9-yl- ]ethyl ⁇ amino)benzonitrile K -320
- (+/-)-7-methyl-2-(morpholin-4-yl)- 9-(l - ⁇ [2-(2H-tetrazol-5-yl)phenyl]amino- ⁇ ethyl)-pyrido[ 1 ,2-a]pyrimid-4-one K -325
- Additional PI3 kinase inhibitors of use herein include 42-(3-hydroxy-2- (hydroxymethyl)-rapamycin 2-methylpropanoate (temsirolimus, Wyeth); 42-0-(2- hydroxyethyl)-rapamycin (Novartis), and 42-(dimethylphopsinoyl)-rapamycin (Ariad).
- Additional PI3 kinase inhibitors which can be used in the methods of the invention include those set forth in US 7,598,377; 7,662,977; 7,544,677; 7,524,850; 7,511,041; and US published applications 2009/0098135; 2009/0029997; 2009/0029998 and
- PI3 kinase inhibitors of use in the present methods further include pharmaceutically acceptable salts, esters and prodrugs of any of the PI3 kinase inhibitors described herein.
- HDAC inhibitor refers to a compound which inhibits the enzymatic activity of one or more isoforms of histone deacetylase.
- the ability of a compound to inhibit HDAC activity can beassessed using methods known in the art, including, but not limited to, the method described herein.
- Suitable HDAC inhibitors include, but are not limited to, hydroxamic acids, cyclic peptides, benzamides and aliphatic acids.
- the HDAC inhibitor is selected from the group consisting of suberoylanilide hydroxamic acid (SAHA), butyric acid, valproic acid, and Romidepsin.
- SAHA suberoylanilide hydroxamic acid
- the HDAC inhibitor is belinostat, mocetinostat, LAQ824, LBH589, CI994, BML-210, M344, MS275, JNJ- 26481585 or MGCD0103.
- the HDAC inhibitor is selected from:
- the HDAC inhibitor is EVP-0334, MGCD-290, CHR-3996 or DAC-0060.
- Additional HDAC inhibitors which can be used in the methods of the invention include those set forth in WO 2008/019025, WO 2006/094068, WO 2007/054719, WO 2005/007091, WO 2010/028193, WO 2008/082646, WO 2007/045962, WO 2005/087724, WO 2005/065681, WO 2004/113366, WO 2004/054999, WO 2003/011851, WO
- HDAC inhibitors of use in the present methods further include pharmaceutically acceptable salts, esters and prodrugs of any of the HDAC inhibitors described herein.
- the inhibitor of PI3 kinase and the HDAC inhibitor are separate compounds.
- the inhibitor of PI3 kinase and the HDAC inhibitor are the same compound, that is, a single bifunctional compound which functions as both an inhibitor of PI3 kinase and an HDAC inhibitor.
- the bifunctional molecule comprises a moiety which inhibits PI3 kinase and a moiety which inhibits histone deacetylase. Suitable bifunctional molecules include those having the general formula A- B-C, where A is a moiety that inhibitors PI3 kinase, C is a moiety which inhibis HDAC and B is a linker.
- the bifunctional molecule is selected from the compounds set forth in US Patent Publication No. 2010/0222343 and US Patent
- the bifunctional compound has the general formula (I):
- q, r and s are independently 0 or 1 , wherein at least one of q, r and s is 1 ; preferably, one of q, r and s is 1 and the rest are 0; n is 0, 1, 2, 3 or 4;
- p is 0, 1 or 2, preferably 0 or 1;
- t is 0 or 1; preferably, when s is 1, t is 0;
- X and Y are independently CRi, N(R 8 ), S or O; wherein when one of X and Y is CRi, the other is N(R 8 ), S or O; preferably X is S and Y is CRi;
- Gi is CRi, S, O, NRio or NS(0) 2 Rio ;
- G 2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or, substituted or unsubstituted heterocyclic;
- G 3 is substituted or unsubstituted Ci-Cg alkyl, substituted or unsubstituted C 2 -Cg alkenyl or substituted or unsubstituted C 2 -Cg alkynyl;
- each R 8 is independently hydrogen, acyl, aliphatic or substituted aliphatic;
- each Ri and R 2 is absent or is independently selected from hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF 3 , CN, N0 2 , sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
- R a is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;
- R b is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;
- Rio is selected from hydrogen, hydroxy, amino, alkoxy, alkylamino, dialkylamino, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; preferably Rio is hydrogen, acyl, aliphatic or substituted aliphatic;
- C is selected from:
- R 32 and R 34 are both present, one of R 32 or R 34 must be hydroxy and if Y 2 is absent, R 34 must be hydroxy; and R 33 is hydrogen or aliphatic group;
- R 12 are independently selected from hydrogen or aliphatic;
- R 2 i, R 22 and R 23 are independently selected from hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF 3 , CN, N0 2 , sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
- each Ri and R 2 is independently absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF 3 , CN, N0 2 , sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, heterocyclylalkyl or substituted heterocyclylalkyl.
- the bifunctional compound is represented by formula (II) or formula (III), or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, or prodrug thereof:
- bifunctional compound in another embodiment, is represented by formula (IV) or (V) as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt or prodrug thereof:
- Gi, G 2 , Ri, R 2 , Rg, n, p, q, r, s, B and C are as defined above; and G 4 is NRg, S or O, preferably S.
- Gi is O.
- the bifunctional compound is represented by formula (VI) and (VII) as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, or prodrug thereof:
- Gi, G 4 , Ri, R 2 , R 3 , Rg, n, m, p, q, , s, B and C are as defined above; and o is 1, 2, 3 or 4.
- q and r are 0 and s is 1. In another preferred embodiment q is 1 while r and s are 0. In another preferred embodiment q and s are 0 and r is 1.
- r is 0 and q is 1.
- B is a Ci-Cg alkyl where one or more CH 2 can be optionally replaced by O, S, S0 2 , NRg or -CONH-, C is -C(0)N(H)OH, and Gi is -O.
- B is a Ci-Cg alkyl where one or more CH 2 can be optionally replaced by O, S, S0 2 NRg or -CONH-, C is -C(0)N(H)OH, and Gi is -NS(0) 2 CH 3 .
- B is an aryl, heteroaryl, Ci-Cio-alkylaryl, C 1 -C 1 0- alkylheteroaryl group, Ci-Cio-alkylheterocyclylaryl, Ci-Cio-alkylheterocyclylheteroaryl, Ci-Cio-alkylheterocyclylaryl-Ci-Cio-alkyl, or Ci-Ci 0 -alkylheterocyclylheteroaryl-Ci-Ci 0 - alkyl group where one or more CH 2 can be optionally replaced by O, S, S0 2 , NRg or - CONH-, and Gi is -O or -NS(0) 2 CH 3 .
- the bifunctional compound is represented by formula (VIII) or (IX) as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt or prodrug thereof:
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indolyl, indazolyl, pyridopyrrolyl, pyrrolyl, imidazolyl, pyrazolyl or benzimidazolyl.
- q is 0 and s is 1. In another preferred embodiment, q is 1 and s is 0.
- B is a Ci-Cg alkyl where one or more CH 2 can be optionally replaced by O, S, S0 2 , NRg or - CONH-, C is -C(0)N(H)OH, and Gi is -O. In another preferred embodiment, B is a Ci-Cg alkyl where one or more CH 2 can be optionally replaced by O, S, S0 2 , NRg or -CONH-, C is -C(0)N(H)OH, and Gi is -NS(0) 2 CH 3 .
- the bifunctional compound is represented by formula X or XI as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt or prodrug thereof:
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indolyl, indazolyl, pyridopyrrolyl, pyrrolyl, imidazolyl, pyrazolyl or benzimidazolyl.
- B is a Ci-Cs alkyl where one or more CH 2 can be optionally replaced by O, S, S0 2 , N(Rg), -CONH-, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic groups, C is -C(0)N(H)OH, and Gi is O.
- B is a Ci-Cg alkyl where one or more CH 2 can be optionally replaced by O, S, S0 2 , NRg, - CONH-, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic groups, C is -C(0)N(H)OH, and Gi is -NS(0) 2 CH 3 .
- the bifunctional compound is represented by formula XII, as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt or prodrug thereof:
- n, p, B, C, Ri, G 2 and R 2 are as defined above.
- the bifunctional compound is represented by formula XIII as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt or prodrug thereof:
- n, p, Y 2 , W, Z, Gi, G 4 , G 2 , Ri, R 2 , R 32 , R 33 and R 34 are as defined above;
- Mi is absent, O, S, NR 8 , Ci-C 6 alkyl, , C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl,
- M 3 is absent, O, NRg, S, SO, S0 2 , CO, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, aryl, heteroaryl, or heterocyclic;
- M 4 is absent, O, NRg, heteroaryl, heterocyclic or aryl; and
- M 5 is absent, Ci-Cg alkyl, C 2 -Cg alkenyl, C 2 -Cgalkynyl, heteroaryl, heterocyclic or aryl.
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indolyl, indazolyl, pyridopyrrolyl, pyrrolyl, imidazolyl, pyrazolyl or benzoimidazolyl.
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl.
- the bifunctional compound is represented by formula (XIV) as illustrated below, or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt or prodrug thereof:
- G ls G 2 , G 4 , n, p, Ri and R 2 are as defined above; t, v and w are independently 0, 1, 2 or 3; u is 0, 1, 2, 3, 4, 5, 6, 7 or 8; G 5 is absent, Ci-Cg alkyl or a Ci-Cg alkyl interrupted by one or more O, S, S(O), S0 2 , N(R 8 ), or C(O); preferably G 5 is -N(R 8 )-Ci-C 4 -alkyl, t is 1 and u is 0;
- G 6 is selected from CRi or NR 8 , wherein Ri and R 8 are as defined above; G 7 is selected from -CRi, -NRg, S or O wherein Ri and Rg are as defined above; or G 7 is selected from -C(Ri) 2 , and -N; R 5 and R 6 are independently selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF 3 , CN, N0 2 , sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indolyl, indazolyl, pyridopyrrolyl, pyrrolyl, imidazolyl, pyrazolyl or benzimidazolyl.
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl.
- G 7 is CRi or N
- the pyrimidine ring is directly bonded to G 7 .
- the bifunctional compound is represented by formula
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indolyl, indazolyl, pyridopyrrolyl, pyrrolyl, imidazolyl, pyrazolyl or benzimidazolyl.
- Gi is O
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl
- G 5 is -N(Rg)-Ci-C 4 -alkyl and u is 0.
- G 2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrrolyl selected from the group:
- m is 1 and R 3 is hydroxyl, hydroxymethyl, amino, acylamino, such as acetylamino, or methylamino.
- R 3 is hydroxyl, hydroxymethyl, amino, acylamino, such as acetylamino, or methylamino.
- G 2 is an optionally substituted indazolyl or benzimidazolyl group selected from the groups shown below:
- R 3 , Rg and m are as defined above.
- G 2 is an optionally substituted monoaryl or monoheteroaryl group.
- G 2 is phenyl, pyridyl, pyrimidyl or pyrrolyl with one or more substituents include but not limited to hydroxyl, hydroxymethyl, amino and substituted amino; Gi is O, G 5 is -N(Rg)-Ci-C4-alkyl and u is 0.
- G 2 can be phenyl, pyridyl, pyrimidyl or pyrrolyl substituted by a hydroxyl, hydroxymethyl, acetylamino, amino or methylamino group.
- Such compounds have significant inhibitory activity toward mTOR, as well as PI3 kinase and HDAC.
- C is: ; where R 33 is selected from hydrogen and lower alkyl.
- the bivalent B is a direct bond or straight- or branched-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkyl, alkyn
- alkylheteroarylalkenyl alkylheteroarylalkynyl, alkenylheteroarylalkyl,
- alkenylheteroarylalkenyl alkenylheteroarylalkynyl, alkynylheteroarylalkyl,
- alkynylheteroarylalkenyl alkynylheteroarylalkynyl, alkylheterocyclylalkyl,
- alkylheterocyclylalkenyl alkylhererocyclylalkynyl, alkenylheterocyclylalkyl,
- alkenylheterocyclylalkenyl alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, or alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), S0 2 , N(R 8 ), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; such divalent B linkers include but are not limited to alkyl, alkenyl, alkynyl, alkylaryl, alkeny
- alkylheterocyclylheteroaryl alkylheterocyclylheteroarylalkyl, alkoxyaryl, alkylaminoaryl, alkoxyalkyl, alkylaminoalkyl, alkylheterocycloalkyl, alkylheteroarylalkyl, alkylamino, N(R 8 )alkenyl, N(R 8 )alkynyl, N(R 8 )alkoxyalkyl, N(R 8 )alkylaminoalkyl,
- N(R 8 )alkylaminocarbonyl N(R 8 )alkylaryl, N(R 8 )alkenylaryl, N(R 8 )alkynylaryl,
- N(R 8 )C(0)alkenyl N(R 8 )C(0)- alkynyl, N(R 8 )C(0)alkylaryl, N(R 8 )C(0)alkenylaryl, N(R 8 )C(0)alkynylaryl, N(R 8 )C(0)alkoxyalkyl, N(R 8 )C(0)alkylaminoalkyl,
- alkenylarylaminoalkylamino alkenylarylalkylaminoalkoxy
- alkenylarylalkylaminoalkylamino alkenylarylalkylaminoalkylamino .
- B is a straight chain alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl,
- alkenylarylalkyl alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl,
- alkynylarylalkenyl alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl,
- alkenylheteroarylalkynyl alkynylheteroarylalkyl, alkynylheteroarylalkenyl,
- alkynylheteroarylalkynyl alkylheterocyclylalkyl, alkylheterocyclylalkenyl,
- alkylhererocyclylalkynyl alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, or alkynylhereroaryl,.
- One or more methylenes can be interrupted or terminated by -0-, -N(R 8 )-, -C(O)-, -C(0)N(R 8 )-, or -C(0)0-.
- the C group is attached to B via an aliphatic moiety within B.
- the linker B is between 1-24 atoms, preferably 4-24 atoms, preferably 4-18 atoms, more preferably 4-12 atoms, and most preferably about 4-10 atoms.
- B is selected from straight chain Ci-Ci 0 alkyl, Ci-Ci 0 alkenyl, Ci-Cio alkynyl, Ci-Cio alkoxy, alkoxyCi-Cioalkoxy, Ci-Cio alkylamino, alkoxyCi- Cioalkylamino, Ci-Cio alkylcarbonylamino, Ci-Cio alkylaminocarbonyl, aryloxyCi- Cioalkoxy, aryloxyCi-Cioalkylamino, aryloxyCi -Cioalkylamino carbonyl, Ci-Cio- alkylaminoalkylaminocarbonyl, Ci-Cio alkyl(N-alkyl)aminoalkyl-aminocarbonyl, alkylaminoalkylamino, alkylcarbonylaminoalkylamino, alkyl(N-alkyl)aminoalkyl-a
- the C group is attached to B via an aliphatic moiety carbon chain, an aryl group or a heteroaryl group within B.
- B is an aryl, heteroaryl, Ci-Cio-alkylaryl, Ci-Cio-alkylheteroaryl group, Ci-Cio-alkylheterocyclylaryl, Ci-Cio- alkylheterocyclylheteroaryl, Ci-Ci 0 -alkylheterocyclylaryl-Ci-Ci 0 -alkyl, or Ci-Ci 0 - alkylheterocyclylheteroaryl-C i-C l o-alkyl group .
- alkyl alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl
- heterocyclyl and the like can be further substituted.
- B is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
- d and e are independently 0, 1, 2, 3, 4, 5, 6, 7 or 8; and R 100 is hydrogen or a group selected from Ci-Cg alkyl, C 2 -C8 alkenyl, C 2 -C8 alkynyl, and C 3 -C 8 cycloalkyl.
- Preferred alkyl groups are -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , - CH(CH 3 )CH 3 , -C(CH 3 ) 2 CH 3 , -C(CH 3 ) 3 .
- Ri 00 is hydrogen or methyl.
- Representative bifunctional compounds of use herein are those selected from Table A below or the geometric isomers, enantiomers, diastereomers, racemates,
- the PI3 kinase and inhibitor and the HDAC inhibitor, or the bifunctional compound is administered as a pharmaceutical composition comprising the active compound and a pharmaceutically acceptable carrier or excipient.
- suitable pharmaceutical compositions comprise any solid or liquid physical form of the active compound.
- the compounds can be in a crystalline form, in amorphous form, and have any particle size. The particles may be micronized, or may be agglomerated, particulate granules, powders, oils, oily suspensions or any other form of solid or liquid physical form.
- Suitable pharmaceutical compositions typically comprise a therapeutically effective amount of an active compound, and a pharmaceutically acceptable carrier.
- Compounds of use in the methods of the invention may be administered by any suitable means, including, without limitation, parenteral, intravenous, intramuscular, subcutaneous, implantation, oral, sublingual, buccal, nasal, pulmonary, transdermal, topical, vaginal, rectal, and transmucosal administrations or the like.
- parenteral intravenous, intramuscular, subcutaneous, implantation, oral, sublingual, buccal, nasal, pulmonary, transdermal, topical, vaginal, rectal, and transmucosal administrations or the like.
- compositions include a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing a compound of the invention as an active ingredient, which is suitable for selected mode of administration.
- the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e., as a solid or a liquid preparation.
- Suitable solid oral formulations include tablets, capsules, pills, granules, pellets, sachets and effervescent, powders, and the like.
- Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
- the composition is formulated in a capsule.
- the compositions of the present invention comprise in addition to the active compound and the inert carrier or diluent, a hard gelatin capsule.
- compositions of the present invention may further comprise a disintegrating agent (e.g., sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium tartrate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulf
- croscarmellose sodium and a lubricant (e.g., magnesium stearate), and may additionally comprise one or more additives selected from a binder, a buffer, a protease inhibitor, a surfactant, a solubilizing agent, a plasticizer, an emulsifier, a stabilizing agent, a viscosity increasing agent, a sweetener, a film forming agent, or any combination thereof.
- compositions of the present invention may be in the form of controlled release or immediate release formulations.
- pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, emulsions or oils.
- non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
- Solutions or suspensions can also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediammetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- compositions may further comprise binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate, Primogel), buffers (e.g., tris-HCL, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat No. 4,522,811.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- compositions that contain an active compound are well understood in the art, for example, by mixing, granulating, or tablet- forming processes.
- the active therapeutic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient.
- the active agents are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions and the like as detailed above.
- the amount of the compound administered to the patient is preferably less than an amount that would cause toxicity in the patient. In certain embodiments, the amount of the compound that is administered to the patient is less than the amount that causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound.
- the concentration of the compound in the patient's plasma is maintained at about 10 nM. In one embodiment, the concentration of the compound in the patient's plasma is maintained at about 25 nM. In one embodiment, the concentration of the compound in the patient's plasma is maintained at about 50 nM. In one embodiment, the concentration of the compound in the patient's plasma is maintained at about 100 nM. In one embodiment, the concentration of the compound in the patient's plasma is maintained at about 500 nM.
- the concentration of the compound in the patient's plasma is maintained at about 1000 nM. In one embodiment, the concentration of the compound in the patient's plasma is maintained at about 2500 nM. In one embodiment, the concentration of the compound in the patient's plasma is maintained at about 5000 nM.
- the optimal amount of the compound that should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.
- an "aliphatic group” or “aliphatic” is non-aromatic moiety that may be saturated (e.g. single bond) or contain one or more units of unsaturation, e.g., double and/or triple bonds.
- An aliphatic group may be straight chained, branched or cyclic, contain carbon, hydrogen or, optionally, one or more heteroatoms and may be substituted or unsubstituted.
- An aliphatic group, when used as a linker preferably contains between about 1 and about 24 atoms, more preferably between about 4 to about 24 atoms, more preferably between about 4-12 atoms, more typically between about 4 and about 8 atoms.
- An aliphatic group when used as a substituent, preferably contains between about 1 and about 24 atoms, more preferably between about 1 to about 10 atoms, more preferably between about 1-8 atoms, more typically between about 1 and about 6 atoms.
- aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted. It is understood that aliphatic groups may include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl groups described herein.
- substituted carbonyl includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom, and tautomeric forms thereof.
- moieties that contain a substituted carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
- carbonyl moiety refers to groups such as “alkylcarbonyl” groups wherein an alkyl group is covalently bound to a carbonyl group, "alkenylcarbonyl” groups wherein an alkenyl group is covalently bound to a carbonyl group, "alkynylcarbonyl” groups wherein an alkynyl group is covalently bound to a carbonyl group, “arylcarbonyl” groups wherein an aryl group is covalently attached to the carbonyl group.
- the term also refers to groups wherein one or more heteroatoms are covalently bonded to the carbonyl moiety.
- the term includes moieties such as, for example, aminocarbonyl moieties, (wherein a nitrogen atom is bound to the carbon of the carbonyl group, e.g., an amide).
- acyl refers to hydrogen, alkyl, partially saturated or fully saturated cycloalkyl, partially saturated or fully saturated heterocycle, aryl, and heteroaryl substituted carbonyl groups.
- acyl includes groups such as (Ci-C 6 )alkanoyl (e.g., formyl, acetyl, propionyl, butyryl, valeryl, caproyl, t-butylacetyl, etc.), (C3-Ce)cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.), heterocyclic carbonyl (e.g., pyrrolidinylcarbonyl, pyrrolid-2-one-5 -carbonyl, piperidinylcarbonyl, piperazinylcarbonyl, tetrahydrofuranylcarbonyl, etc.
- the alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be any one of the groups described in the respective definitions.
- the acyl group may be unsubstituted or optionally substituted with one or more substituents (typically, one to three substituents) independently selected from the group of substituents listed below in the definition for "substituted” or the alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be substituted as described above in the preferred and more preferred list of substituents, respectively.
- alkyl embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about eight carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like.
- alkenyl embraces linear or branched radicals having at least one carbon- carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl” radicals having two to about ten carbon atoms and more preferably about two to about eight carbon atoms. Examples of alkenyl radicals include ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl.
- alkenyl and “lower alkenyl” embrace radicals having "cis” and “trans” orientations, or alternatively, "E” and "Z” orientations.
- alkynyl embraces linear or branched radicals having at least one carbon- carbon triple bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl” radicals having two to about ten carbon atoms and more preferably about two to about eight carbon atoms.
- alkynyl radicals examples include propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2- butynyl and 1-pentynyl.
- cycloalkyl embraces saturated carbocyclic radicals having three to about twelve carbon atoms.
- cycloalkyl embraces saturated carbocyclic radicals having three to about twelve carbon atoms.
- More preferred cycloalkyl radicals are "lower cycloalkyl” radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- cycloalkenyl embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. Cycloalkenyl radicals that are partially unsaturated carbocyclic radicals that contain two double bonds (that may or may not be conjugated) can be called “cycloalkyldienyl". More preferred cycloalkenyl radicals are "lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl.
- alkoxy embraces linear or branched oxy-containing radicals each having alkyl portions of one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to about ten carbon atoms and more preferably having one to about eight carbon atoms.
- radicals examples include methoxy, ethoxy, propoxy, butoxy and tert-butoxy.
- alkoxyalkyl embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.
- aryl alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
- aryl embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl.
- heterocyclyl saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called “heterocyclyl”, “heterocycloalkenyl” and “heteroaryl”
- heteroatoms may be selected from nitrogen, sulfur and oxygen.
- saturated heterocyclyl radicals include saturated 3 to 6-membered
- heteromonocyclic group containing 1 to 4 nitrogen atoms e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.
- saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms e.g. morpholinyl, etc.
- saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms e.g., thiazolidinyl, etc.
- partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.
- Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals.
- the term "heterocycle” also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like.
- heteroaryl embraces unsaturated heterocyclyl radicals.
- heteroaryl radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-l,2,4-triazolyl, 1H-1,2,3- triazolyl, 2H-l,2,3-triazolyl, etc.) tetrazolyl (e.g.
- unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[l,5-b]pyridazinyl, etc.), etc.;
- unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom for example, pyranyl, furyl, etc.
- unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom for example, thienyl, etc.
- unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.
- unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms e.g. benzoxazolyl, benzoxadiazolyl, etc.
- unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms for example, thiazolyl, thiadiazolyl (e.g., 1,2,4- thiadiazolyl, 1,3,4- thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl,
- heterocycloalkyl embraces heterocyclo-substituted alkyl radicals. More preferred heterocycloalkyl radicals are "lower heterocycloalkyl” radicals having one to six carbon atoms in the heterocyclo radicals.
- alkylthio embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom.
- Preferred alkylthio radicals have alkyl radicals of one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkylthio radicals have alkyl radicals are "lower alkylthio" radicals having one to about ten carbon atoms. Most preferred are alkylthio radicals having lower alkyl radicals of one to about eight carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio.
- aralkyl or "arylalkyl” embrace aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
- aryloxy embraces aryl radicals attached through an oxygen atom to other radicals.
- aralkoxy or "arylalkoxy” embrace aralkyl radicals attached through an oxygen atom to other radicals.
- aminoalkyl embraces alkyl radicals substituted with amino radicals.
- Preferred aminoalkyl radicals have alkyl radicals having about one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred aminoalkyl radicals are "lower aminoalkyl” that have alkyl radicals having one to about ten carbon atoms. Most preferred are aminoalkyl radicals having lower alkyl radicals having one to eight carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like.
- alkylamino denotes amino groups which are substituted with one or two alkyl radicals.
- Preferred alkylamino radicals have alkyl radicals having about one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkylamino radicals are "lower alkylamino” that have alkyl radicals having one to about ten carbon atoms. Most preferred are alkylamino radicals having lower alkyl radicals having one to about eight carbon atoms.
- Suitable lower alkylamino may be monosubstituted N- alkylamino or disubstituted ⁇ , ⁇ -alkylamino, such as N-methylamino, N-ethylamino, N,N- dimethylamino, ⁇ , ⁇ -diethylamino or the like.
- linker means an organic moiety that connects two parts of a compound.
- Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NRg, C(O), C(0)NH, SO, S0 2 , S0 2 NH or a chain of atoms, such as substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl,
- heteroarylalkynyl heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkenyl, alkenylheteroarylalkenyl, alkenylhetero
- alkenylheteroarylalkynyl alkynylheteroarylalkyl, alkynylheteroarylalkenyl,
- alkynylheteroarylalkynyl alkylheterocyclylalkyl, alkylheterocyclylalkenyl,
- alkylhererocyclylalkynyl alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl,
- the linker B is between 1-24 atoms, preferably 4-24 atoms, preferably 4-18 atoms, more preferably 4-12 atoms, and most preferably about 4-10 atoms.
- the linker is a C(0)NH(alkyl) chain or an alkoxy chain. It is to be understood that an asymmetric linker, such as alkylaryl, can connect two structurally distinct moieties in either of its two possible orientations.
- substituted refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy
- chemical moieties are defined and referred to throughout can be univalent chemical moieties (e.g., alkyl, aryl, etc.) or multivalent moieties under the appropriate structural circumstances clear to those skilled in the art.
- an "alkyl” moiety can be referred to a monovalent radical (e.g. CH 3 -CH 2 -), or in other instances, a bivalent linking moiety can be "alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH 2 -CH 2 -), which is equivalent to the term
- alkylene alkylene
- alkoxy alkoxy
- alkylamino alkyloxy
- alkylthio alkyl
- alkyl alkylthio
- alkyl alkyl
- alkyl alkenyl
- alkynyl alkynyl
- aliphatic or "cycloalkyl”
- halogen refers to an atom selected from fluorine, chlorine, bromine and iodine.
- the term "aberrant proliferation” refers to abnormal cell growth.
- adjunct therapy encompasses treatment of a subject with agents that reduce or avoid side effects associated with the combination therapy of the present invention, including, but not limited to, those agents, for example, that reduce the toxic effect of anticancer drugs, e.g., bone resorption inhibitors, cardioprotective agents; prevent or reduce the incidence of nausea and vomiting associated with chemotherapy, radiotherapy or operation; or reduce the incidence of infection associated with the administration of myelosuppressive anticancer drugs.
- apoptosis refers to programmed cell death as signaled by the nuclei in normally functioning human and animal cells when age or state of cell health and condition dictates.
- An “apoptosis inducing agent” triggers the process of programmed cell death.
- cancer denotes a class of diseases or disorders
- compound is defined herein to include pharmaceutically acceptable salts, solvates, hydrates, polymorphs, enantiomers, diastereoisomers, racemates and the like of the compounds having a formula as set forth herein.
- device refers to any appliance, usually mechanical or electrical, designed to perform a particular function.
- displasia refers to abnormal cell growth, and typically refers to the earliest form of pre-cancerous lesion recognizable in a biopsy by a pathologist.
- a therapeutically effective amount of a compound or combination of compounds with respect to the subject method of treatment refers to an amount of the subject compound or the amounts of two or more compounds in
- a neoplasia disorder including, but is not limited to: 1) reduction in the number of cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration into peripheral organs; 4) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 5) inhibition, to some extent, of tumor growth; 6) relieving or reducing to some extent one or more of the symptoms associated with the disorder; and/or 7) relieving or reducing the side effects associated with the administration of anticancer agents.
- hyperplasia refers to excessive cell division or growth.
- an "immunotherapeutic agent” refers to agents used to transfer the immunity of an immune donor, e.g., another person or an animal, to a host by inoculation.
- the term embraces the use of serum or gamma globulin containing performed antibodies produced by another individual or an animal; nonspecific systemic stimulation; adjuvants; active specific immunotherapy; and adoptive immunotherapy.
- Adoptive immunotherapy refers to the treatment of a disease by therapy or agents that include host inoculation of sensitized lymphocytes, transfer factor, immune R A, or antibodies in serum or gamma globulin.
- inhibitors in the context of neoplasia, tumor growth or tumor cell growth, may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, among others. In the extreme, complete inhibition, is referred to herein as prevention or chemoprevention.
- Metastasis refers to the migration of cancer cells from the original tumor site through the blood and lymph vessels to produce cancers in other tissues. Metastasis also is the term used for a secondary cancer growing at a distant site.
- Neoplasm refers to an abnormal mass of tissue that results from excessive cell division. Neoplasms may be benign (not cancerous), or malignant (cancerous) and may also be called a tumor. The term “neoplasia” is the pathological process that results in tumor formation.
- pre-cancerous refers to a condition that is not malignant, but is likely to become malignant if left untreated.
- PI3 kinase related disease or disorder refers to a disease or disorder characterized by inappropriate phosphoinositide-3 -kinase activity or over-activity of the phosphoinositide-3 -kinase. Inappropriate activity refers to either; (i) PI3 kinase expression in cells which normally do not express PI3 kinase; (ii) increased PI3 kinase expression leading to unwanted cell proliferation, differentiation and/or growth; or, (iii) decreased PI3 kinase expression leading to unwanted reductions in cell proliferation, differentiation and/or growth.
- Over-activity of PI3 kinase refers to either amplification of the gene encoding a particular PI3 kinase or production of a level of PI3 kinase activity which can correlate with a cell proliferation, differentiation and/or growth disorder (that is, as the level of the PI3 kinase increases, the severity of one or more of the symptoms of the cellular disorder increases).
- a "radio therapeutic agent” refers to the use of electromagnetic or particulate radiation in the treatment of neoplasia.
- recurrence refers to the return of cancer after a period of remission. This may be due to incomplete removal of cells from the initial cancer and may occur locally (the same site of initial cancer), regionally (in vicinity of initial cancer, possibly in the lymph nodes or tissue), and/or distally as a result of metastasis.
- treatment refers to any process, action, application, therapy, or the like, wherein a mammal, including a human being, is subject to medical aid with the object of improving the mammal's condition, directly or indirectly.
- vaccine includes agents that induce the patient's immune system to mount an immune response against the tumor by attacking cells that express tumor associated antigens (Teas).
- the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the
- nontoxic acid addition salts include, but are not limited to, salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy- ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pam
- alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
- ester refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
- Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
- esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and
- prodrugs refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention.
- Prodrug as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of the invention.
- prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard- Larsen, et al, (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8: 1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration, such as sterile pyrogen-free water. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- pre-cancerous refers to a condition that is not malignant, but is likely to become malignant if left untreated.
- subject refers to an animal.
- the animal is a mammal. More preferably the mammal is a human.
- a subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.
- the compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties.
- modifications are known in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- the synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid
- transformations and protecting group methodologies useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
- Certain of the compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids.
- the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
- Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art.
- any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
- compositions of the present invention comprise a
- pharmaceutically acceptable carrier or excipient means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose;
- cyclodextrins such as alpha- (a), beta- ( ⁇ ) and gamma- ( ⁇ ) cyclodextrins; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lub
- compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection.
- the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
- the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adjuvants such as wetting agents, e
- Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite
- compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
- the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
- Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
- Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
- dosage forms can be made by dissolving or dispensing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin.
- the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- a therapeutic composition of the invention is formulated and administered to the patient in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system.
- Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter et al, U.S. Pat. No.
- a therapeutically effective amount of a compound or combination of compounds is an amount which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment.
- the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
- An effective amount of the compound described above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and like factors well known in the medical arts.
- the total daily dose of the compounds of this invention administered to a human or other animal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight.
- Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
- treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.
- the compounds of the formulae described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.1 to about 500 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug.
- the methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect.
- the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion.
- Such administration can be used as a chronic or acute therapy.
- the amount of active ingredient that may be combined with pharmaceutically excipients or carriers to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- a typical preparation will contain from about 5% to about 95% active compound (w/w).
- such preparations may contain from about 20% to about 80%) active compound.
- a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
- the dosage or frequency of administration, or both may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level.
- Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- Step lb 4-Bromo-iH-indazole (Compound 0106-3)
- chloroform (5 mL) was added potassium acetate (0.28 g, 2.82 mmol). The mixture was cooled with ice-water bath and then acetic anhydride (0.50 mL, 5.37 mmol) was added to it. Ice-water bath was then removed and the resulting mixture was stirred at room temperature for 10 minutes after which time a white gelatinous solid formed. 18-Crown-6 (0.14 g, 0.54 mmol) was then added followed by isoamyl nitrite (0.80 mL, 5.90 mmol). The mixture was then heated under reflux for 18 hours. The reaction mixture was allowed to cool, and was partitioned between chloroform (3 x 10 mL) and saturated aqueous sodium hydrogen carbonate (10 mL).
- Step lh 4-(2-Cloro-6-((4-(methylthioperoxy)piperazin-l-yl)methyl)thieno[3,2-d] pyrimidin-4-yl)morpholine (Compound 0113)
- Step li 4-(2-Chloro-6-((4-(methylthioperoxy)piperazin-l-yl)methyl)thieno[3,2-d] pyrimidin-4-yl)morpholine (Compound 0114)
- Step lj Ethyl 5-(4-(6-((4-(methylsulfonyl)piperazin-l-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidin-2-yl)-2H-indazol-2-yl)pentanoate (Compound 0116-3) and ethyl 5-(4-(6-((4-(methylsulfonyl)piperazin-l-yl)methyl)-4- morpholinothieno[3,2- d]pyrimidin-2-yl)-lH-indazol-l-yl)pentanoate (Compound 0115-3)
- Step lk N-Hydroxy-5-(4-(6-((4-(methylsulfonyl)piperazin- 1 -yl)methyl)-4- morpholinothien-[3 ,2-d]pyrimidin-2-yl)- 1 H-indazol- 1 -yl)pentanamide (Compound 3)
- Step 2a Ethyl 6-(4-(6-((4-(methylsulfonyl)piperazin-l-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidin-2-yl)-2H-indazol-2-yl)hexanoate (Compound 0116-4) and ethyl 3 -(4-(6-((4-(methylsulfonyl)piperazin- 1 -yl)methyl)-4- morpholinothieno [3 ,2- d]pyrimidin-2-yl)-l H-indazol- l-yl)propanoate (Compound 0115-4)
- Step 2b N-hydroxy-3-(4-(6-((4-(methylsulfonyl)piperazin- 1 -yl)methyl)-4- morpholinothieno [3 ,2-d]pyrimidin-2-yl)- 1 H-indazol- 1 -yl)propanamide (Compound 4)
- the title compound 4 was prepared as a yellow solid (45 mg, 22%>) from 0115-4
- Step 3a Ethyl 7-(4-(6-((4-(methylsulfonyl)piperazin-l-yl)methyl)- 4- morpholinothieno[3,2-d]pyrimidin-2-yl)-2H-indazol-2-yl)heptanoate (Compound 0116-5) and ethyl 7-(4-(6-((4-(methylsulfonyl)piperazin-l-yl)methyl)-4- morpholinothieno[3,2- d]pyrimidin-2-yl)-l H-indazol- l-yl)heptanoate (Compound 0115-5)
- the title compound 0115-5 (110 mg, 27%) and 0116-5 (60 mg, 16%) were prepared from 0114 (280 mg, 0.55 mmol) , ethyl 7-bromoheptanoate (133 mg, 0.65 mmol) and potassium carbonate (152 mg, 1.10 mmol) in
- Step 3b N-hydroxy-7-(4-(6-((4-(methylsulfonyl)piperazin- 1 -yl)methyl)-4- morpholinothieno[3,2-d]pyrimidin-2-yl)-lH-indazol-l-yl)heptanamide (Compound 5)
- the title compound 5 was prepared as a white solid (70 mg, 71 >) from 0115-5 (100 mg, 0.15 mmol) and freshly prepared hydroxylamine methanol solution (4.0 mL) using a procedure similar to that described for compound 3 (Example 1): mp 127-130 °C.
- the title compound 7 was prepared as a white solid (35 mg, 47%>) from 0116-3 (60 mg, 0.12 mmol) and freshly prepared hydroxylamine methanol solution (4.0 mL) using a procedure similar to that described for compound 3 (Example 1): mp 146-169 °C.
- the title compound 8 was prepared as a yellow solid (15 mg, 11%) from 0116-4 (140 mg, 0.21 mmol) and freshly prepared hydroxylamine methanol solution (5.0 mL) using a procedure similar to that described for compound 3 (Example 1): mp 124-125 °C.
- the title compound 9 was prepared as a white solid (45 mg, 76%) from 0116-5 (60 mg, 0.09 mmol) and freshly prepared hydroxylamine methanol solution (4.0 mL) using a procedure similar to that described for compound 3 (Example 1): mp 123-126 °C.
- Step 7b 4-(2-Chloro-6-(piperazin-l-ylmethyl)thieno[3,2-(i]pyrimidin-4-yl) morpholine (Compound 0202)
- Step 7c Ethyl 5-(4-((2-chloro-4-morpholinothieno[3,2- ⁇ i]pyrimidin-6-yl)methyl) piperazin-l-yl)pentanoate (Compound 0203-11)
- Step 7d Ethyl 5-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-(i] pyrimidin-6- yl)methyl)piperazin-l-yl)pentanoate (Compound 0204-11)
- Step 7e 5-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-(i] pyrimidin-6- yl)methyl)piperazin-l-yl)-N-hydroxypentanamide (Compound 11)
- the title compound 0203-12 was prepared as a gray solid (0.57 g, 82%) from 0202
- Step 8b Ethyl 6-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-(i]pyrimidin -6- yl)methyl)piperazin-l-yl)hexanoate (Compound 0204-12)
- the title compound 0204-12 was prepared as a white solid (56 mg, 16%>) from 0203-12 (295 mg, 0.61 mmol), 0107-3 (164 mg, 0.67 mmol), NaHC0 3 (150 mg, 1.79 mmol) and Pd(dppf) 2 Ci2 (23 mg, 0.031 mmol) in toluene (5.6 mL), ethanol (3 mL) and water (1.5 mL) using a procedure similar to that described for compound 0204-11
- Step 8c 6-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-(i]pyrimidin- 6- yl)methyl)piperazin-l-yl)-N-hydroxyhexanamide (Compound 12)
- the title compound 12 was prepared as a white solid (15 mg, 13 >) from 0204-12 (120 mg, 0.21 mmol) and freshly prepared hydroxylamine methanol solution (1.0 mL, 1.77 mol/L) using a procedure similar to that described for compound 3 (Example 1): m.p.
- Example 9 Preparation of 7-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-i/] pyrimidin-6-yl)methyl)piperazin-l-yl)- V-hydroxyheptanamide (Compound 13)
- Step 9a Ethyl 7-(4-((2-chloro-4-morpholinothieno[3,2- ⁇ i]pyrimidin-6-yl)methyl) piperazin- 1 -yl)heptanoate (Compound 0203-13)
- Step 9b Ethyl 7-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-(i] pyrimidin-6- yl)methyl)piperazin-l-yl)heptanoate (Compound 0204-13)
- Step 9c 7-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-(i]pyrimidin-6- yl)methyl)piperazin-l-yl)-N-hydroxyheptanamide (Compound 13)
- the title compound 13 was prepared as a white solid (25 mg, 37%>) from 0204-13
- Step 10a (Z)-Ethyl-2-(ethoxymethyl)-3-methoxyacrylate (Compound 0302)
- Step 10b Ethyl 2-oxo-l,2,3,4-tetrahydropyrimidine-5-carboxylate (Compound 0303)
- Step 10c Ethyl 2-oxo-l,2-dihydropyrimidine-5-carboxylate (Compound 0304)
- Step lOf Ethyl 2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)
- Step lOg Ethyl 2-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d] pyrimidin-6- yl)methyl)piperazin- 1 -yl)pyrimidine-5 -carboxylate (Compound 0308)
- the title compound 0308 was prepared as a yellow solid (60 mg, 23%) from 0307 (220 mg, 0.44 mmol), 0107-3 (161 mg, 0.66 mmol), NaHC0 3 (111 mg, 1.32 mmol) and Pd(dppf)2Cl2 (19 mg, 0.022 mmol) in toluene (4.7 mL), ethanol (2.8 mL) and water (1.2 mL) using a procedure similar to that described for compound 0204-11 (Example 7):
- the title compound 14 was prepared as a yellow solid (30 mg, 52%) from 0308 (60 mg, 0.10 mmol) and freshly prepared hydroxylamine methanol solution (3.0 mL, 1.77 mol/L) using a procedure similar to that described for compound 3 (Example 1): mp 209- 221 °C.
- Step 11a Ethyl 2-(4-(aminomethyl)piperidin-l-yl)pyrimidine-5-carboxylate
- Step 11c Ethyl 2-(4-(((2-(lH-indazol-4-yl)-4-morpholinothieno [3,2-d]pyrimidin-6-yl)me thylamino)methyl)piperidin- 1 -yl)pyrimidine-5-carboxylate (Compound 0403-15)
- the title compound 0403 was prepared as a white solid (120 mg, 17%) from 0402 (630 mg, 1.18 mmol), 0107-3 (580 mg, 2.37 mmol), NaHC0 3 (297 mg, 3.54 mmol) and Pd(dppf) 2 Cl 2 (25 mg, 0.036 mmol) in toluene (11 mL), ethanol (6.6 mL) and water (3.1 mL) using a procedure similar to that described for compound 0204-11 (Example 7):
- the title compound 15 was prepared as a white solid (30 mg, 63%) from 0403 (50 mg, 0.08 mmol) and freshly prepared hydroxylamine methanol solution (3.0 mL, 1.77 mol/L) using a procedure similar to that described for compound 3 (Example 1): mp 170- 172 °C.
- Step 12a (2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methanol (Compound 0501) To a mixture of compound 0112 (500 mg, 1.77 mmol) in methanol (10 mL) was added sodium borohydride (200 mg, 5.3 mmol). The mixture was stirred at room temperature
- Step 12b 4-(6-(Bromomethyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine
- Step 12c (2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-N- methylmethanamine (Compound 0503-54)
- Step 12d Ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)
- Step 12e Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl) methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0505)
- Step 12f 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin- 6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 54)
- the title compound 54 was prepared as a white solid (17 mg, 15%) from 0505-54 (120 mg, 0.22 mmol) and freshly prepared hydroxylamine methanol solution (4.0 mL, 1.77 mol/L) using a procedure similar to that described for compound 3 (Example 1):
- Example 13 Preparation of 2-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d] pyrimidin-6-yl)methylamino)-N-hydroxypyrimidine-5-carboxamide (Compound 53)
- Step 13a (2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methanamine (Compound 0503-53)
- Step 13b Ethyl 2-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methylamino) pyrimidine-5-carboxylate (Compound 0504-53)
- Step 13c Ethyl 2-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl) methylamino)pyrimidine-5-carboxylate (Compound 0505-53)
- Step 13d 2-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)
- the title compound 53 was prepared as a light yellow solid (19 mg, 24%>) from 0505-53 (80 mg, 0.15 mmol) and freshly prepared hydroxylamine methanol solution (5.0 mL, 1.77 mol/L) using a procedure similar to that described for compound 3 (Example 1): m.p. 234-237 °C.
- Step 14b Ethyl 2-(4-((((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)methyl)piperidin- 1 -yl)pyrimidine-5 -carboxylate (Compound
- Step 14c 2-(4-((((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)methyl)piperidin- 1 -yl)-N-hydroxypyrimidine-5 -carboxamide (Compound 16)
- hydroxylamine hydrochloride (4.67 g, 67 mmol) in methanol (24 mL) at 0 °C
- potassium hydroxide 5.61 g, 100 mmol
- methanol 14 mL
- Step 15a Ethyl 4-(tert-butoxycarbonyl((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)amino)butanoate (Compound 0404-41)
- Ethyl 4-aminobutanoate hydrochloride (1.97 g, 11.77 mmol) was solved in chloroform (30 mL) and the pH of mixture was adjusted to 8 ⁇ 9 with triethylamine, then compound 0112 (1.66 g, 5.88 mmol) and tetraisopyl titanate (2.01 g, 7.06 mmol) were added and the mixture was stirred at reflux overnight. Removed the solvent, then 1 ,2- dichloroethane (50 mL) and sodium cyanborohydride (1.48 g, 23.53 mmol) were added and then stirred at room temperature for 12 h.
- Step 16a Methyl 5-(tert-butoxycarbonyl((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)amino)pentanoate (Compound 0404-42)
- Step 16b Methyl 5-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(tert-butoxycarbonyl)amino)pentanoate(Compound 0405-42)
- Step 16c 5-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)-N-hydroxypentanamide(Compound 42)
- the title compound 42 was prepared as a white solid (23 mg, 13.9%) from 0405-42 (260 mg, 0.45 mmol) and freshly prepared hydroxylamine methanol solution (8.0 mL) followed by deprotection using a procedure similar to that described for compound 41 (Example 15): m.p 145-147 °C.
- Step 17a Ethyl 6-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)hexanoate (Compound 0404-43)
- Step 17b Ethyl 6-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)hexanoate (Compound 0405-43) A mixture of compound 0404-43 (343 mg, 0.80 mmol), 0107-3 (294 mg, 1.2 mmol), sodium hydrogen carbonate (294 mg, 2.4 mmol) and
- Step 17c 6-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)-N-hydroxyhexanamide (43)
- Step 18a Ethyl 7-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)heptanoate (Compound 0404-44)
- Step 18b Ethyl 7-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)heptanoate (Compound 0405-44)
- Step 18c 7-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)-N-hydroxyheptanamide (Compound 44)
- the title compound 44 was prepared (37 mg, 24%) as a yellow solid from 0405-44 (160 mg, 0.31 mmol) and freshly prepared hydroxylamine methanol solution (3.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 188-190 °C.
- Example 19 Preparation of 4-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)-N-hydroxybutanamide (Compound 101)
- Step 19a Ethyl 4-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)butanoate (Compound 0404-101)
- Step 19b Ethyl 4-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)butanoate (Compound 111-48-3)
- Step 19c 4-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxybutanamide (Compound 101)
- the title compound 101 was prepared (160 mg, 88%) as a yellow solid from 0405-
- Example 20 Preparation of 5-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)-N-hydroxypentanamide (Compound 102)
- Step 20a Methyl 5-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pentanoate (Compound 0404-102)
- Step 20b Methyl 5-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pentanoate (Compound 0405-102)
- Step 20c 5-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypentanamide (Compound 102)
- the title compound 102 was prepared (60 mg, 25%) as a yellow solid from 0405- 102 (240 mg, 0.48 mmol) and freshly prepared hydroxylamine methanol solution (8.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 120-122 °C.
- Example 21 Preparation of 6-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)-N-hydroxyhexanamide (Compound 103)
- Step 21a Ethyl 6-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)hexanoate (Compound 0404-103)
- Step 21b Ethyl 6-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)hexanoate (Compound 0405-103)
- Step 21c 6-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxyhexanamide (Compound 103)
- the title compound 103 was prepared (75 mg, 41%) as a white solid from 0405-103 (190 mg, 0.22 mmol) and freshly prepared hydroxylamine methanol solution (4.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 1 15-118 °C.
- Example 22 Preparation of 7-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2- d] pyrimidin-6-yl)methyl)(methyl)amino)-N-hydr oxyheptanamide (Compound 104)
- Step 22a Ethyl 7-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)heptanoate (Compound 0404-104)
- Step 22b Ethyl 7-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)heptanoate (Compound 0405-104)
- Step 22c 7-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxyheptanamide (Compound 104)
- the title compound 104 was prepared (65 mg, 55 >) as a white solid from 0405-104
- Step 23a 3-Bromo-5-fluoro-2-methylbenzenamine (Compound 0104-69)
- Step 23b 4-Bromo-6-fluoro-lH-indazole (Compound 0106-69)
- the title compound 0107-69 (700 mg, 57%) was prepared as a yellow solid from 0106-69 (1.0 g, 4.65 mmol), bis(pinacolato)diboron (1.77 g, 6.98 mmol), PdC12(dppf)2 (380 mg, 0.47 mmol) and dried potassium acetate (1.37 g, 14.0 mmol) in dioxane (40 mL) using a procedure similar to that described for compound 0107-3 (Example 1): LCMS: 263 [M+l] + .
- Step 23d Ethyl 2-(((2-(6-fluoro-lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5 -carboxylate (Compound 0505-69)
- Step 23e 2-(((2-(6-Fluoro-lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5 -carboxamide (Compound 69)
- the title compound 69 was prepared (24 mg, 25%) as a yellow solid from 0505-69 (100 mg, 0.18 mmol) and freshly prepared hydroxylamine methanol solution (10.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 215-217 °C.
- Step 24b Ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(neopentyl) amino)pyrimidine-5-carboxylate (Compound 0504-83)
- Step 24c Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl) (neopentyl)amino)pyrimidine-5-carboxylate (Compound 0505-83)
- Step 24d 2-(((2-( 1 H-indazol-4-yl)-4-morpholinothieno [3 ,2-d]pyrimidin-6- yl)methyl)(neopentyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 83)
- the title compound 83 was prepared (191 mg, 65%) as a yellow solid from 0505-83 (300 mg, 0.51 mmol) and freshly prepared hydroxylamine methanol solution (20.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 240-242 °C.
- Step 25a N-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)propan-l -amine (Compound 0503-84)
- Step 25b Ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(propyl)amino)pyrimidine-5-carboxylate (Compound 0504-84)
- Step 25c Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methy l)(propyl)amino)pyrimidine-5 -carboxylate (Compound 0505-84)
- the title compound 0505-84 was prepared (240 mg, 82%) as a white solid from 0504-84 (250 mg, 0.52 mmol), 0107-3 (154 mg, 0.63 mmol), sodium hydrogen carbonate (132 mg, 1.57 mmol) and bis(triphenylphosphine)palladium(II) chloride (18.5 mg, 0.026 mmol) in toluene (8 mL), ethanol (5 mL) and water (2 mL) using a procedure similar to that described for compound 0505-83 (Example 24): LCMS: 559 [M+l] + ; 1H NMR (400 MHz, DMSO-de
- Step 25d 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(propyl)amino)-N-hydroxypyrimidine-5 -carboxamide (Compound 84)
- the title compound 84 was prepared (189 mg, 81%) as a white solid from 0505-84 (240 mg, 0.43 mmol) and freshly prepared hydroxylamine methanol solution (16.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 224-226 °C.
- Step 26a N-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)butan-l -amine (Compound 0503-85)
- the title compound 0503-85 was prepared (430 mg, 88%>) as a light yellow solid from 0502 (500mg, 1.43 mmol) and butan-l-amine (5mL) in methanol (30 mL) using a procedure similar to that described for compound 0503-84 (Example 25): LCMS: 341
- Step 26b Ethyl 2-(butyl((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)amino)pyrimidine-5-carboxylate (Compound 0504-84)
- Step 26c Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(butyl)amino)pyrimidine-5-carboxylate (Compound 0505-85)
- Step 26d 2-(((2-( 1 H-indazol-4-yl)-4-morpholinothieno [3 ,2-d]pyrimidin-6- yl)methyl)(butyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 85)
- the title compound 85 was prepared (131 mg, 53%) as an off-white solid from 0505-85 (255 mg, 0.45 mmol) and freshly prepared hydroxylamine methanol solution (16.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 234-236 °C.
- Step 27a 2-((2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methylamino)ethanol (Compound 0503-86)
- the title compound 0503-86 was prepared (230 mg, 41 >) as a light yellow solid from 0502 (600 mg, 1.72 mmol) and 2-aminoethanol (6 mL) in methanol (60 mL) using a procedure similar to that described for compound 0503-84 (Example 25): LCMS: 329
- Step 27b Ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(2- hydroxyethyl)amino)pyrimidine-5-carboxylate (Compound 0504-86)
- the title compound 0504-86 was prepared (170 mg, 51%) as a white solid from
- Step 27c Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(2-hydroxyethyl)amino)pyrimidine-5-carboxylate (0505-86)
- the title compound 0505-86 was prepared (120 mg, 60%) as a white solid from
- Step 27d 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(2- hydroxyethyl)amino)-N-hydroxypyrimidine-5-carboxamide (86)
- the title compound 86 was prepared (42 mg, 36%>) as an off-white solid from 0505- 86 (120 mg, 0.21 mmol) and freshly prepared hydroxylamine methanol solution (8.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 190-194 °C.
- Step 28a N-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-2- methoxyethanamine (Compound 0503-90)
- Step 28b Ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(2- methoxyethyl)amino)pyrimidine-5-carboxylate (Compound 0504-90)
- the title compound 0504-90 was prepared (400 mg, 81%) as a yellow solid from
- Step 28c Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(2-methoxyethyl)amino)pyrimidine-5 -carboxylate (Compound 0505-90)
- Step 28d 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(2- methoxyethyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 90)
- the title compound 90 was prepared (180 mg, 71%) as a white solid from 0505-90 (260 mg, 0.45 mmol) and freshly prepared hydroxylamine methanol solution (15.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 219-222 °C.
- LCMS 482 [M+l] + .
- 1H-NMR 400 MHz.
- Step 29a N-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-2-methylpropan- 1-amine (Compound 0503-93)
- the title compound 0503-93 was prepared (0.6 g, 88%) as a yellow solid from 0502 (694 g, 2.0 mmol), 2-methylpropan-l -amine (1.5 g, 20 mmol) and DIPEA (2.6 g, 20 mmol) in MeOH (5 mL) using a procedure similar to that described for compound 0503-84 (Example 25): LCMS: 341 [M+l] + .
- Step 29b Ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(isobutyl) amino)pyrimidine-5-carboxylate (Compound 0504-93)
- the title compound 0504-93 was prepared (500 mg, 57%>) as a yellow solid from
- Step 29c Ethyl 2-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl) (isobutyl)amino)pyrimidine-5-carboxylate (Compound 0505-93)
- the title compound 0505-93 was prepared (257 mg, 91 >) as a white solid from
- Step 29d 2-(((2-( 1 H-indazol-4-yl)-4-morpholinothieno [3 ,2-d]pyrimidin-6- yl)methyl)(isobutyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 93)
- the title compound 93 was prepared (90mg, 26 %) as a white solid from 0505-93 (357 mg, 0.6 mmol) and freshly prepared hydroxylamine methanol solution (20.0 mL) using a procedure similar to that described for compound 3 (Example 1): m.p. 196-198 °C.
- Step 30a Isopropyl 6-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)nicotinate (Compound 0309-76)
- Step 30b Methyl 6-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)nicotinate (Compound 0310-76)
- Step 30c 6-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)-N-hydroxynicotinamide (Compound 76)
- the title compound 76 was prepared (23 mg, 16%>) as a brown solid from 0310-76-2
- Step 31a Ethyl 4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)benzoate (Compound 0309-78)
- Step 31b Ethyl 4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)benzoate (Compound 0310-78)
- the title compound, 0310-78 was prepared (85 mg, 33%) as a white solid from 0309-78 (216 mg, 0.5 mmol), 0107-3 (256 mg, 0.53 mmol), sodium hydrogen carbonate (126 mg, 1.5 mmol) and bis(triphenylphosphine)palladium( II ) chloride (18 mg, 0025 mmol) in toluene (4.0 mL), ethanol (2.5 mL) and water (1.5 mL) using a procedure similar to that described for compound 0310-76 (Example 30).
- Step 31c 4-((2-( 1 H-indazol-4-yl)-4-morpholinothieno [3 ,2-d]pyrimidin-6- yl)methylamino)-N-hydroxybenzamide (Compound 78)
- the title compound 78 was prepared (41 mg, 28%) as a yellow solid from 0310-78 (150 mg, 0.29 mmol) and freshly prepared hydroxylamine methanol solution (10.0 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 180-183 °C.
- Example 32 Preparation of (E)-3-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2- d] pyrimidin-6-yl)methylamino)phenyl)-N-hydroxyacrylamide (Compound 80)
- Step 32a (E)-ethyl 3-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)phenyl)acrylate (Compound 0309-80)
- Step 32b (E)-ethyl 3-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)phenyl)acrylae (Compound 0310-80)
- the title compound, 0310-80 was prepared (490 mg, 69%) as a light yellow solid from 0309-80 (600 mg, 1.31 mmol), 0107-3 (383 mg, 1.57 mmol), sodium hydrogen carbonate (329 mg, 3.92 mmol) and bis(triphenylphosphine)palladium( II ) chloride (46 mg, 0.065 mmol) in toluene (16.0 mL), ethanol (10 mL) and water (4 mL) using a procedure similar to that described for compound 0310-76 (Example 30).
- Step 32c (E)-3-(4-((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methylamino)phenyl)-N-hydroxyacrylamide (Compound 80)
- the title compound 80 was prepared (71 mg, 15%) as a light yellow solid from 0310-80 (490 mg, 0.91 mmol) and freshly prepared hydroxylamine methanol solution (20.0 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. >300
- Step 33a (E)-ethyl 3-(4-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl) (methyl)amino)phenyl)acrylate (Compound 0309-81)
- Step 33b (E)-ethyl 3-(4-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl) methyl)(methyl)amino)phenyl)acrylate (Compound 0310-81)
- 0309- 81 (240 mg, 0.5 mmol), 0107-3 (135 mg, 0.55 mmol), NaHC0 3 (126 mg, 1.5 mmol), and bis(triphenylphosphine)palladium( II ) chloride (18 mg, 0.025 mmol) in toluene (4 mL), ethanol (2 mL) and water (1 mL) using a procedure similar to that described for compound
- Step 33c (E)-3-(4-(((2-(lH-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)phenyl)-N-hydroxyacrylamide (Compound 81)
- the title compound 81 was prepared (24 mg, 10 %>) as a light yellow solid from
- Step 34a N-(3-bromophenyl)acetamide (Compound 0601-107) To the solution of 3-bromoaniline (6.3 g, 63.7mmol) in CH 2 CI 2 (50 mL) was added acetyl chloride (3.75 g, 47.7 mmol) and TEA (7.4 g, 73.4 mmol) at 0 °C, stirred for 2 hours. The mixture was washed with water, brine, dried over Na 2 S0 4 , filtered, and concentrated under reduced pressure to give the title compound 0601-107 (7.8 g, 99.3%) as a brown solid. LCMS: 215 [M+l] + .
- Step 34b N-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)acetamide (Compound 0602-107)
- Step 34c Ethyl 2-(((2-(3-acetamidophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603-107)
- the title compound, 0603-107 was prepared (160 mg, 99%) as a gray solid from 0504-54 (130 mg, 0.30 mmol), 0602-107 (84 mg, 0.7 mmol), sodium hydrogen carbonate (74 mg, 0.88 mmol) and bis(triphenylphosphine)palladium( II ) chloride (12 mg, 0.014 mmol) in toluene (2.5 mL), ethanol (1.6 mL) and water (0.7 mL) using a procedure similar to that described for compound 0310-76 (Example 30).
- Step 34d 2-(((2-(3-acetamidophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 107)
- the title compound 107 was prepared (64 mg, 50%) as a white solid from 0603-107
- Step 35a Ethyl 6-(2-chloro-4-morpholinothieno [3, 2-d] pyrimidin-6-ylamino) hexanoate (Compound 0602-108)
- Step 35b Ethyl 2-(((2-(3-(dimethylamino)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603-108)
- the title compound 0603-108 was prepared (245 mg, 91%) as a white solid from 0504-54 (224 mg, 0.5 mmol), 0602-108 (490 mg, 2.0 mmol), NaHC0 3 (126 mg, 1.5 mmol) and bis(triphenylphosphine)palladium( II ) chloride (18 mg, 0.025 mmol) in toluene (4 mL), ethanol (2 mL) and water (1 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 35c 2-(((2-(3-(dimethylamino)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 108)
- the title compound 108 was prepared (35 mg, 15 %>) as a yellow solid from 0603- 108 (130 mg, 0.23 mmol) and freshly prepared hydroxylamine methanol solution (20 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 172-175 °C.
- Step 36a Ethyl 2-(methyl((4-morpholino-2-(pyridin-3-yl)thieno[3,2-d]pyrimidin-6- yl)methyl)amino)pyrimidine-5-carboxylate (compound 0603-109)
- the title compound, 0603-109 was prepared (140 mg, 94%) as a yellow solid from 0504-54 (135 mg, 0.30 mmol), 3-pyridylboronic acid (41 mg, 0.60 mmol), NaHC0 3 (76 mg, 0.90 mmol) and Pd(dppf)2Cl2 (11 mg, 0.015 mmol) in toluene (2.5 mL), ethanol (1.6 mL) and water (0.7 mL) using a procedure similar to that described for compound 0603- 107 (Example 30).
- LCMS 492 [M+l] + .
- Step 36b N-hydroxy-2-(methyl((4-morpholino-2-(pyridin-3-yl)thieno[3,2-d]pyrimidin-6- yl)methyl)amino)pyrimidine-5-carboxamide (Compound 109)
- the title compound 109 was prepared (30 mg, 44%) as a yellow solid from 0603-
- Step 37a 5-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-amine (Compound 0602-110)
- the title compound, 0602-110 was prepared (500 mg, 23%) as an oil from 2-amino- 5-bromopyridine (1.73 g, 10 mmol), bis(pinacolato)diboron (3.81 g, 15 mmol), potassium acetate (3 g, 30 mmol), and PdC ⁇ dppfh (408 mg, 5 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- the title compound, 0603-110 was prepared (200 mg, 59%) as a white solid from 0602-110 (300 mg, 0.67 mmol), 0504-54 (176 mg, 0.8 mmol), NaHC0 3 (172 mg, 2mmol) and bis(triphenylphosphine)palladium( II ) chloride (23 mg, 0.0335 mmol) in toluene (8 mL), ethanol (5 mL) and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 37c 2-(((2-(6-Aminopyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 110)
- the title compound 110 was prepared (25 mg, 13 %) as a yellow solid from 0603- 110 (200 mg, 0.4 mmol) and freshly prepared hydroxylamine methanol solution (20 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 175-181 °C.
- Step 38a 5-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (Compound 0602-115)
- Step 38b Ethyl 2-(((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin- 6- yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603-115)
- the title compound, 0603-115 was prepared (110 mg, 51%) as a white solid from 0602-115 (120 mg, 0.54 mmol), 0504-54 (200 mg, 0.45 mmol), NaHC0 3 (114 mg, 1.35 mmol), and bis(triphenylphosphine)palladium( II ) chloride (16 mg, 0.0225 mmol) in toluene (8 mL), ethanol (5 mL) and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 38c 2-(((2-(2-Aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 115)
- the title compound 115 was prepared (25 mg, 23 %) as a yellow solid from 0603-
- Step 39a 5-Bromo-N-methylpyrimidin-2-amine (compound 0601-116) and 5-bromo-N,N- dimethylpyrimidin-2-amine (compound 0601-117)
- Step 39b N-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (Compound 0602-116)
- the title compound, 0602-116 was prepared (350 mg, 50%) as yellow solid from 5- bromo-N-methylpyrimidin-2-amine (0.56 g, 3 mmol), bis(pinacolato)diboron (1.14 g, 4.5 mmol), potassium acetate (0.88 g, 9 mmol), and Pd(dppf) 2 Ci 2 (490 mg, 0.6 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 39c Ethyl 2-(methyl((2-(2-(methylamino)pyrimidin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)amino)pyrimidine-5-carboxylate (Compound 0603-116)
- the title compound, 0603-116 was prepared (100 mg, 64%) as a yellow solid from 0504-54 (135 mg, 0.30 mmol), 0602-116 (106 mg, 0.45 mmol), NaHC0 3 (76 mg, 0.90 mmol) and Pd(dppf) 2 Ci 2 (11 mg, 0.015 mmol) in toluene (2.5 mL), ethanol (1.6 mL) and water (0.7 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 39d N-hydroxy-2-(methyl((2-(2-(methylamino)pyrimidin-5-yl)-4- morpholinothieno [3 ,2-d]pyrimidin-6-yl)methyl)amino)pyrimidine-5 -carboxamide
- the title compound 116 was prepared (50 mg, 54%>) as a yellow solid from 0603-
- Step 40a N,N-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (Compound 0602-117)
- Step 40b Ethyl 2-(((2-(2-(dimethylamino)pyrimidin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (0603-117)
- Step 40c 2-(((2-(2-(Dimethylamino)pyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin- 6-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 117)
- the title compound 117 was prepared (60 mg, 66%) as a yellow solid from 0603- 117 (93 mg, 0.17 mmol) and freshly prepared hydroxylamine methanol solution (5 mL) using a procedure similar to that described for compound 3 (Example 1). m.p.: 200-206 °C.
- Step 41a Ethyl 2-(methyl((4-morpholino-2-(pyrimidin-5-yl)thieno[3,2-d]pyrimidin-6- yl)methyl)amino)pyrimidine-5 -carboxylate (Compound 0603-119)
- the title compound, 0603-119 was prepared (160 mg, 46%>) as a white solid from 0504-54 (314 mg, 0.7 mmol), pyrimidin-2-ylboronic acid (175 mg, 1.4 mmol), NaHC0 3 (176 mg, 2.1 mmol) and bis(triphenylphosphine)palladium( II ) chloride (24 mg, 0.03 mmol) in toluene (8 mL), ethanol (5 mL) and water (3 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 41b N-hydroxy-2-(methyl((4-morpholino-2-(pyrimidin-5 -yl)thieno [3 ,2-d]pyrimidin- 6-yl)methyl)amino)pyrimidine-5-carboxamide (Compound 1 19)
- the title compound 119 was prepared (60 mg, 40%) as a white solid from 0603-1 19 (150 mg, 0.3 mmol) and freshly prepared hydroxylamine methanol solution (5 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 159-160 °C.
- Step 42a 5-Bromo-2-methylpyrimidine (Compound 0601-120)
- Step 42b 2-Methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidine (Compound 0602-120)
- the title compound, 0602-120 was prepared (100 mg, 52%) as a yellow oil from 0601-120 (150 mg, 0.87 mmol), bis(pinacolato)diboron (331 mg, 1.3 mmol), PdCl 2 (dppf) 2 (21 mg, 0.026 mmol) and dried potassium acetate (256 mg, 2.62 mmol)using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 42c Ethyl 2-(methyl((2-(2-methylpyrimidin-5-yl)-4-morpholinothieno[3,2-d] pyrimidin-6-yl)methyl)amino)pyrimidine-5 -carboxylate (Compound 0603-120)
- the title compound, 0603-120 was prepared (210 mg, 74%) as a off-white solid from 0504-54 (250 mg, 0.56 mmol), 0602-120 (880 mg, 4 mmol), sodium hydrogen carbonate (168 mg, 2 mmol), and bis(triphenylphosphine)palladium( II ) chloride (23 mg, 0.03 mmol) in toluene (8 mL), ethanol (5mL) and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 42d N-hydroxy-2-(methyl((2-(2-methylpyrimidin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)amino)pyrimidine-5 -carboxamide (Compound 120)
- the title compound 120 was prepared (150 mg, 73%) as a white solid from 0603-
- Step 43a 5-Bromo-2-ethylpyrimidine (0601-121)
- Step 43b 2-Ethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidine (Compound 0602-121)
- the title compound, 0602-121 was prepared (crude 3.7 g) as a yellow oil from 0601-121 (1.7 g, 9.1 mmol), bis(pinacolato)diboron (3.5 g, 13.6 mmol), PdCl 2 (dppf) 2 (222 mg, 0.27 mmol) and potassium acetate (2.7 g, 27 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- the title compound, 0603-121 was prepared (120 mg, 41%>) as a yellow solid from 0504-54 (250 mg, 0.56 mmol), 0602-121 (3.7 g, crude), sodium hydrogen carbonate (168 mg, 2 mmol) and bis(triphenylphosphine)palladium( II ) chloride (23 mg, 0.03 mmol) in toluene (8 mL), ethanol (5mL) and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 43d N-Hydroxy-2-(methyl((2-(2-methylpyrimidin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)amino)pyrimidine-5 -carboxamide (Compound 121)
- the title compound 121 was prepared (66 mg, 56%) as a white solid from 0603-121
- Step 44a 5-Bromo-4-methylpyrimidin-2-amine (Compound 0601-125)
- Step 44b 4-Methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (Compound 0602-125)
- the title compound, 0602-125 was prepared (430 mg, 69%) as a grey solid from 0601-125 (500 mg, 2.66 mmol), bis(pinacolato)diboron (1.01 g, 4.0 mmol), PdCl 2 (dppf) 2 (217.2 mg, 0.27 mmol), potassium acetate (783 mg, 7.98 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 44c Ethyl 2-(((2-(2-amino-4-methylpyrimidin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603-125)
- the title compound, 0603-125 was prepared (160 mg, 55%) as a white solid from
- Step 44d 2-(((2-(2-Amino-4-methylpyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin- 6-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 125)
- the title compound 125 was prepared (92 mg, 62 %) as a white solid from 0603- 125 (150 mg, 0.29 mmol) and freshly prepared hydroxylamine methanol solution (20 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 195-198 °C.
- Step 45a 2-(3-Methoxyphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (Compound 0602-130)
- the title compound, 0602-130 was prepared (800 mg, 68%) as an oil from 1-bromo- methoxybenzene (930 mg, 5.0 mmol), bis(pinacolato)diboron (2.54 g, 10 mmol), potassium acetate (1.47 g, 15 mmol), and PdCi 2 (dppf) 2 (204 mg, 0.25 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 45b Ethyl 2-(((2-(3-methoxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5 -carboxylate (Compound 0603-130)
- the title compound, 0603-130 was prepared (120 mg, 51%) as a white solid from 0602-130 (126 mg, 0.54 mmol), 0504-54 (200 mg, 0.45 mmol), NaHC0 3 (114 mg, 1.35 mmol), and bis(triphenylphosphine)palladium( II ) chloride (16 mg, 0.0225 mmol) in toluene (8 mL), ethanol (5 mL), and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 45c N-hydroxy-2-(((2-(3-methoxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxamide (Compound 130)
- the title compound 130 was prepared (15 mg, 15 %) as a yellow solid from 0603- 130 (110 mg, 0.2 mmol) and freshly prepared hydroxylamine methanol solution (20 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 179-181 °C.
- Step 46a 3-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)phenol (Compound 0602-132)
- the title compound, 0602-132 was prepared (600 mg, 68%) as an oil from 3- bromophenol (700 mg, 4.0 mmol), bis(pinacolato)diboron (1.5 g, 6 mmol), potassium acetate (1.2 g, 12 mmol), and PdC12(dppf)2 (163 mg, 0.2 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- LCMS 221 [M+l] + .
- Step 46b Ethyl 2-(((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603-132)
- the title compound, 0603-132 was prepared (160 mg, 47%) as a white solid from 0602-132 (300 mg, 0.67 mmol), 0504-54 (176 mg, 0.8 mmol), NaHC0 3 (172 mg, 2mmol), and bis(triphenylphosphine)palladium( II ) chloride (23 mg, 0.0335 mmol) in toluene (8 mL), ethanol (5 mL) and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 46c N-hydroxy-2-(((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxamide (Compound 132)
- the title compound 132 was prepared (53 mg, 34 %) as a yellow solid from 0603- 132 (160 mg, 0.32 mmol) and freshly prepared hydroxylamine methanol solution (20 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 175-181 °C.
- Step 47a Ethyl-2-(((2-(3-aminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (compound 0603-134)
- Step 47b 2-(((2-(3-Aminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 134)
- the title compound 134 was prepared (35 mg, 28%) as a white solid from 0603-134 (130 mg, 0.25 mmol) and freshly prepared hydroxylamine methanol solution (4 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 179-182 °C.
- Step 48a N-(4-bromobenzyl)acetamide (Compound 0601-135)
- Step 48b N-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzyl)acetamide
- Step 48c Methyl 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl) (methyl)amino)pyrimidine-5-carboxylate (Compound 0603-135)
- Step 49a N-(3-bromobenzyl)acetamide (Compound 0601-137)
- Step 49b N-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzyl)acetamide
- the title compound, 0602-137 was prepared (1.0 g, 72%) as a yellow solid from 0601-137 (1.2 g, 5 mmol), bis(pinacolato)diboron (1.9 g, 7.5 mmol), potassium acetate (1.47 g, 15 mmol), and Pd(dppf) 2 Cl 2 (410 mg, 0.5 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 49c Methyl 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl) methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603-137)
- 0602-137 400 mg, 1.46 mmol
- 0504-54 522 mg, 1.16 mmol
- NaHC0 3 368 mg, 4.4 mmol
- bis(triphenylphosphine)palladium( II ) chloride 104 mg, 0.146 mmol
- toluene 4 mL
- ethanol 2 mL
- water 0.5 mL
- the title compound 137 was prepared (46 mg, 18%) as a light yellow solid from 0603-137 (250 mg, 0.5 mmol) and freshly prepared hydroxylamine methanol solution (20 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 173-176 °C.
- Step 50a (3-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)methanol (Compound 0602-138)
- the title compound, 0602-138 was prepared (300 mg, 43%) as a yellow oil from m- bromobenzyl alcohol (0.56 g, 3 mmol), bis(pinacolato)diboron (1.14 g, 4.5 mmol), potassium acetate (1.32 g, 9 mmol), and Pd(dppf) 2 Cl 2 (490 mg, 0.6 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 50b Ethyl 2-(((2-(3-(hydroxymethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5 -carboxylate (0603-138)
- the title compound, 0603-138 was prepared (140 mg, 90%) as a white solid from 0504-54 (135 mg, 0.30 mmol), 0602-138 (105 mg, 0.45 mmol), NaHC0 3 (76 mg, 0.90 mmol), and Pd(dppf) 2 Ci2 (11 mg, 0.015 mmol) in toluene (2.5 mL), ethanol (1.6 mL), and water (0.7 mL) using a procedure similar to that described for compound 0603-107
- Step 50c N-hydroxy-2-(((2-(3-(hydroxymethyl)phenyl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5 -carboxamide
- the title compound 138 was prepared (30 mg, 44%>) as a light yellow solid from 0603-138 (70 mg, 0.13 mmol) and freshly prepared hydroxylamine methanol solution (10 mL) using a procedure similar to that described for compound 3 (Example 1). mp 160-164 °C.
- Step 51a l-Bromo-3-(methoxymethyl)benzene (Compound 0601-139) To a solution of m-bromobenzyl alcohol (1.0 g, 5.3 mmol) in THF (10 mL) was added NaH (0.26 g, 10.6 mmol) at 0 °C, stirred for 10 minutes, followed by addition of iodomethane (1.1 g, 7.9 mmol). The resulting reaction mixture was stirred for 1 hour. To the mixture ethyl acetate (30 mL) was added, washed with water, brine, dried over Na 2 S0 4 , filtered, and concentrated under reduced pressure to give the title compound 0601-139 (1.0 g, 93%) as an oil.
- Step 51c Ethyl-2-(((2-(3-(methoxymethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5-carboxylate (Compound 0603 - 139)
- the title compound, 0603-139 was prepared (180 mg, 71%) as a white solid from 0504-54 (210 mg, 0.46 mmol), 0602-139 (174 mg, 0.7 mmol), sodium hydrogen carbonate (118 mg, 1.4 mmol), and bis(triphenylphosphine)palladium( II ) chloride (16 mg, 0.02 mmol) in toluene (8 mL), ethanol (2 mL), and water (1 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 51d N-hydroxy-2-(((2-(3-(methoxymethyl)phenyl)-4-morpholinothieno[3 ,2- d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide (Compound 139)
- the title compound 139 was prepared (56 mg, 47%) as an orange solid from 0603- 139 (120 mg, 0.22 mmol) and freshly prepared hydroxylamine methanol solution (8 mL) using a procedure similar to that described for compound 3 (Example 1). m.p. 178-181 °C.
- Step 52a (4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)methanol (compound 0602-140)
- the title compound, 0602-140 was prepared (670 mg, 94%) as an oil from (4- bromophenyl)methanol (0.56 g, 3 mmol), bis(pinacolato)diboron (1.14 g, 4.5 mmol), potassium acetate (1.32 g, 9 mmol), and PdCl 2 (dppf) 2 (490 mg, 0.6 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 52b Ethyl 2-(((2-(4-(hydroxymethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5 -carboxylate (compound 0603-140)
- the title compound, 0603-140 was prepared (120 mg, 77%) as a white solid from
- Step 52c N-Hydroxy-2-(((2-(4-(hydroxymethyl)phenyl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide (compound 140)
- the title compound 140 was prepared (61 mg, 63%>) as a yellow solid from 0603-
- Step 53b 2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzyl acetate (Compound 0602- 141)
- the title compound, 0602-141 was prepared (2.3 g, 80%) as an oil from 0601-141 (2.4 g, 10.5 mmol), bis(pinacolato)diboron (4.1 g, 16.3 mmol), potassium acetate (3.2 g, 32.7 mmol), and PdCl 2 (dppf) 2 (89 mg, 0.11 mmol) using a procedure similar to that described for compound 0602-107 (Example 34).
- Step 53c Ethyl 2-(((2-(2-(hydroxymethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5 -carboxylate (Compound 0603-141)
- the title compound, 0603-141 was prepared (80 mg, 17%) as a white solid from 0504-54 (420 mg, 0.92 mmol), 0602-141 (386 mg, 1.4 mmol), sodium hydrogen carbonate (236 mg, 2.8 mmol), and bis(triphenylphosphine)palladium( II ) chloride (32 mg, 0.04 mmol) in toluene (8 mL), ethanol (4 mL), and water (2 mL) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 53d N-hydroxy-2-(((2-(2-(hydroxymethyl)phenyl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methy l)(methyl)amino)pyrimidine-5 -carboxamide (Compound 141)
- the title compound 141 was prepared (58 mg, 37%) as a yellow solid from 0603-
- Step 54b 3-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (Compound 0602- 142)
- Step 54c Ethyl 2-(((2-(3-carbamoylphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)pyrimidine-5 -carboxylate (Compound 0603-142)
- the title compound, 0603-142 was prepared (180 mg, 50%>) as a yellow solid from 0504-54 (305 mg, 0.68 mmol), 0602-142 (200 mg, 0.81 mmol), Pd(PPh 3 ) 2 Cl 2 (21 mg, 0.03 mmol), and NaHC0 3 (171 mg, 2.04 mmol) in toluene (5 mL), ethanol (3 ml), and water (1.3 ml) using a procedure similar to that described for compound 0603-107 (Example 30).
- Step 54d 2-(((2-(3-carbamoylphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 142).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32491210P | 2010-04-16 | 2010-04-16 | |
PCT/US2011/032683 WO2011130628A1 (fr) | 2010-04-16 | 2011-04-15 | Traitement de cancers présentant des mutations k-ras |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2557923A1 true EP2557923A1 (fr) | 2013-02-20 |
EP2557923A4 EP2557923A4 (fr) | 2013-10-23 |
Family
ID=44799046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11769663.3A Withdrawn EP2557923A4 (fr) | 2010-04-16 | 2011-04-15 | Traitement de cancers présentant des mutations k-ras |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2557923A4 (fr) |
JP (1) | JP2013525308A (fr) |
CN (1) | CN102970868A (fr) |
AU (1) | AU2011239537A1 (fr) |
CA (1) | CA2795952A1 (fr) |
WO (1) | WO2011130628A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2710A (en) * | 2006-09-15 | 2013-07-30 | Pfizer Prod Inc | Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors |
WO2010080996A1 (fr) | 2009-01-08 | 2010-07-15 | Curis, Inc. | Inhibiteurs de phosphoinositide 3-kinase avec une fraction de liaison au zinc |
PL2694075T3 (pl) | 2011-04-01 | 2016-09-30 | Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk | |
AU2012340869B2 (en) * | 2011-11-23 | 2017-03-02 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase C |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3053926B1 (fr) * | 2013-09-30 | 2018-08-08 | Shanghai Yingli Pharmaceutical Co. Ltd. | Composé de pyrimidine condensée, intermédiaire, procédé de préparation s'y rapportant et composition et application correspondantes |
WO2015054099A1 (fr) * | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinaisons d'inhibiteurs d'histone désacétylase et d'inhibiteurs d'her2 ou de pi3k |
PT3546461T (pt) * | 2013-11-15 | 2021-10-18 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[ 1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, seus sais e métodos de utilização dos mesmos em terapia de combinação |
CN103601745B (zh) * | 2013-11-26 | 2017-01-18 | 大连联化化学有限公司 | 一种通用的乙酰氨基吡啶硼酸频哪醇酯的制备方法 |
CA3158795A1 (en) * | 2014-03-31 | 2015-10-08 | The Scripps Research Institute | Pharmacophore for trail induction |
CN104131034B (zh) * | 2014-06-19 | 2017-04-05 | 中山大学 | 一种嵌合载体及其制备方法和应用 |
US10420341B2 (en) | 2015-01-30 | 2019-09-24 | Basf Se | Herbicidal phenylpyrimidines |
WO2016169417A1 (fr) * | 2015-04-21 | 2016-10-27 | 成都金瑞长青生物科技有限公司 | Dérivés de purinyl-n-hydroxylpyrimidine-formamide, leur procédé de préparation et leur utilisation |
CN105037345B (zh) * | 2015-06-09 | 2019-01-25 | 天津渤海职业技术学院 | 抗肿瘤化合物、其制备方法和用途 |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
MX2019002212A (es) | 2016-08-24 | 2019-07-08 | Arqule Inc | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. |
TW201817731A (zh) | 2016-09-29 | 2018-05-16 | 日商第一三共股份有限公司 | [2-(1-甲基-1h-吡唑-4-基)-6-( 啉-4-基)-9h-嘌呤-8-基][4-( 啉-4-基)哌啶-1-基]甲酮及其製藥上容許鹽之結晶 |
CN111315735B (zh) * | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
WO2019073031A1 (fr) * | 2017-10-13 | 2019-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polythérapie du cancer du pancréas |
US20210137939A1 (en) * | 2018-05-10 | 2021-05-13 | University Of Louisville Research Foundation, Inc. | Inhibitors of the ras oncoprotein, methods of making and methods of use thereof |
BR112021004371A2 (pt) | 2018-09-11 | 2021-05-25 | Curis Inc. | terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco |
US20230078755A1 (en) | 2018-12-19 | 2023-03-16 | Shy Therapeutics, Llc | Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease |
EP3935050A4 (fr) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | Composés hétérocycliques pour traitement médical |
IL297979A (en) | 2020-05-08 | 2023-01-01 | Halia Therapeutics Inc | Inhibitors of nek7 kinase |
CN115768427A (zh) * | 2020-06-04 | 2023-03-07 | 皮莱环球有限责任公司 | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 |
CN113735830A (zh) * | 2021-10-11 | 2021-12-03 | 成都自豪药业有限公司 | 一类羟肟酸衍生物及其应用 |
WO2024041519A1 (fr) * | 2022-08-24 | 2024-02-29 | 上海璎黎药业有限公司 | Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097449A1 (fr) * | 2005-03-15 | 2006-09-21 | Menarini International Operations Luxembourg S.A. | N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques |
WO2008076447A2 (fr) * | 2006-12-15 | 2008-06-26 | Ordway Research Institute | Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci |
WO2009129335A2 (fr) * | 2008-04-15 | 2009-10-22 | Pharmacyclics, Inc. | Inhibiteurs sélectifs de l'histone désacétylase |
WO2009155659A1 (fr) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Polythérapie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2671845C (fr) * | 2006-12-07 | 2015-03-24 | Genentech, Inc. | Composes inhibiteurs de la phosphoinositide 3-kinase et procedes d'utilisation |
KR20090110913A (ko) * | 2007-02-15 | 2009-10-23 | 노파르티스 아게 | Lbh589와 암을 치료하기 위한 다른 치료제와의 조합물 |
WO2010080996A1 (fr) * | 2009-01-08 | 2010-07-15 | Curis, Inc. | Inhibiteurs de phosphoinositide 3-kinase avec une fraction de liaison au zinc |
-
2011
- 2011-04-15 CN CN2011800290564A patent/CN102970868A/zh active Pending
- 2011-04-15 WO PCT/US2011/032683 patent/WO2011130628A1/fr active Application Filing
- 2011-04-15 EP EP11769663.3A patent/EP2557923A4/fr not_active Withdrawn
- 2011-04-15 JP JP2013505177A patent/JP2013525308A/ja active Pending
- 2011-04-15 AU AU2011239537A patent/AU2011239537A1/en not_active Abandoned
- 2011-04-15 CA CA2795952A patent/CA2795952A1/fr not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097449A1 (fr) * | 2005-03-15 | 2006-09-21 | Menarini International Operations Luxembourg S.A. | N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques |
WO2008076447A2 (fr) * | 2006-12-15 | 2008-06-26 | Ordway Research Institute | Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci |
WO2009129335A2 (fr) * | 2008-04-15 | 2009-10-22 | Pharmacyclics, Inc. | Inhibiteurs sélectifs de l'histone désacétylase |
WO2009155659A1 (fr) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Polythérapie |
Non-Patent Citations (14)
Title |
---|
CHIA-WEI CHOU ET AL: "HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells", PLOS ONE, vol. 6, no. 3, 25 March 2011 (2011-03-25), page e18087, XP055078579, DOI: 10.1371/journal.pone.0018087 * |
DENLINGER ET AL: "Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 130, no. 5, 1 November 2005 (2005-11-01), pages 1422-1429, XP005127283, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2005.06.051 * |
E Lopez-Crapez ET AL: "Rapid and large-scale method to detect K-ras gene mutations in tumor samples", Clinical Chemistry, 1 January 1997 (1997-01-01), pages 936-942, XP055078570, Retrieved from the Internet: URL:http://www.clinchem.org/content/43/6/936.full.pdf+html [retrieved on 2013-09-10] * |
FRANKLIN WILBUR A ET AL: "KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cance", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 12, no. 1, 1 January 2010 (2010-01-01), pages 43-50, XP009168344, ISSN: 1525-1578 * |
G. J. RIELY ET AL: "KRAS Mutations in Non-Small Cell Lung Cancer", PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY, vol. 6, no. 2, 15 April 2009 (2009-04-15), pages 201-205, XP055024772, ISSN: 1546-3222, DOI: 10.1513/pats.200809-107LC * |
JEET GANDHI ET AL: "Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 2, 24 February 2009 (2009-02-24), pages E4576-1, XP002677508, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0004576 * |
KRYPUY MICHAEL ET AL: "High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 21 December 2006 (2006-12-21), page 295, XP021023081, ISSN: 1471-2407, DOI: 10.1186/1471-2407-6-295 * |
M A LEA ET AL: "Induction of Differentiation of Colon Cancer Cells by Combined Inhibition of Kinases and Histone Deacetylase", ANTICANCER RESEARCH, vol. 27, 1 January 2007 (2007-01-01), pages 741-748, XP055079030, * |
N SUNAGA ET AL: "Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy", MOLECULAR CANCER THERAPEUTICS, vol. 10, 1 January 2011 (2011-01-01), pages 336-346, XP055079048, * |
PERGOLIZZI ROBERT G ET AL: "Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas", CANCER INVESTIGATION, vol. 11, no. 1, 1993, pages 25-32, XP008164834, ISSN: 0735-7907 * |
REDDY G K: "EARLY CLINICAL DATA AND POTENTIAL CLINICAL UTILITY OF NOVEL HISTONE DEACETYLASE INHIBITORS IN PROSTATE CANCER", CLINICAL PROSTATE CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 4, no. 2, 1 January 2005 (2005-01-01) , pages 83-85, XP009079218, ISSN: 1540-0352 * |
See also references of WO2011130628A1 * |
WANG QINGDING ET AL: "Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2002, vol. 8, no. 6, June 2002 (2002-06), pages 1940-1947, XP055079069, ISSN: 1078-0432 * |
YU X-D ET AL: "Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 13, no. 2, 1 March 2007 (2007-03-01), pages 105-113, XP008111377, ISSN: 1528-9117 * |
Also Published As
Publication number | Publication date |
---|---|
AU2011239537A1 (en) | 2012-11-15 |
EP2557923A4 (fr) | 2013-10-23 |
CA2795952A1 (fr) | 2011-10-20 |
WO2011130628A1 (fr) | 2011-10-20 |
JP2013525308A (ja) | 2013-06-20 |
CN102970868A (zh) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2557923A1 (fr) | Traitement de cancers présentant des mutations k-ras | |
US10894795B2 (en) | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | |
US20130102595A1 (en) | Treatment of cancers having k-ras mutations | |
CN102625803A (zh) | 药学上有用的杂环-取代的内酰胺 | |
CN104119331A (zh) | 烯基化合物及其使用方法和用途 | |
AU2013206342A1 (en) | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1179472 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130924 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/19 20060101ALI20130918BHEP Ipc: A61K 45/06 20060101ALI20130918BHEP Ipc: A61K 31/167 20060101AFI20130918BHEP Ipc: A61K 31/496 20060101ALI20130918BHEP Ipc: A61K 31/4985 20060101ALI20130918BHEP Ipc: A61K 31/16 20060101ALI20130918BHEP Ipc: A61P 35/00 20060101ALI20130918BHEP Ipc: A61K 31/38 20060101ALI20130918BHEP Ipc: A61K 31/5355 20060101ALI20130918BHEP Ipc: A61K 31/343 20060101ALI20130918BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140423 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1179472 Country of ref document: HK |